[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4tYsP6N7ueG4tpzwxkgGyTYTMrECB8ja87T-kQAQsZw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":37,"phaseBuckets":38,"rows":45},"US Department of Veterans Affairs",[4],676,false,0,64,374335,543,[13,16,19,22,25,28,31,34],{"name":14,"count":15},"Spinal Cord Injury",35,{"name":17,"count":18},"Depression",30,{"name":20,"count":21},"Stroke",28,{"name":23,"count":24},"Schizophrenia",26,{"name":26,"count":27},"Diabetes",23,{"name":29,"count":30},"Hypertension",21,{"name":32,"count":33},"Diabetes Mellitus",19,{"name":35,"count":36},"Stress Disorders, Post-Traumatic",13,[],[39,40,41,42,43,44],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[46,93,130,165,209,237,262,280,307,333,351,375,393,411,429,447,465,483,508,534,552,570,596,614,639,666,691,714,739,757,782,800,823,862,885,911,929,956,974,999,1024,1050,1076,1094,1112,1134,1152,1170,1188,1216,1234,1260,1278,1302,1329,1347,1374,1392,1410,1434,1452,1475,1499,1517,1544,1562,1585,1612,1630,1657,1681,1712,1734,1760,1786,1809,1832,1854,1875,1898,1916,1934,1952,1977,2005,2033,2051,2069,2095,2116,2139,2157,2181,2204,2228,2254,2272,2295,2320,2345,2363,2381,2405,2423,2444,2466,2489,2514,2537,2562,2623,2663,2704,2736,2769,2795,2826,2854,2880,2915,2937,2965,2987,3019,3043,3066,3093,3111,3129,3147,3171,3193,3217,3235,3253,3276,3299,3317,3341,3359,3381,3405,3423,3441,3464,3482,3500,3523,3546,3572,3598,3621,3643,3671,3689,3707,3725,3748,3770,3793,3816,3839,3862,3884,3907,3925,3946,3969,3994,4012,4036,4054,4080,4098,4122,4140],{"intervention":47,"totalTrials":48,"cells":49},"Olanzapine",3,{"EARLY_PHASE1":50,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":58,"NA":91},{"trials":51,"activeCount":8},[],{"trials":53,"activeCount":8},[],{"trials":55,"activeCount":8},[],{"trials":57,"activeCount":8},[],{"trials":59,"activeCount":8},[60,71,80],{"nctId":61,"briefTitle":62,"status":63,"phases":64,"completion":65,"start":66,"conditions":67,"interventions":69},"NCT00108368","The Effects of Risperidone and Olanzapine on Thinking","COMPLETED",[43],"2006-03","2003-10",[23,68],"Psychotic Disorders",[70,47],"Risperidone",{"nctId":72,"briefTitle":73,"status":63,"phases":74,"completion":75,"start":76,"conditions":77,"interventions":78},"NCT00018668","Antipsychotic Response in Schizophrenia",[43],"2004-09","2000-10",[23],[70,47,79],"Quetiapine",{"nctId":81,"briefTitle":82,"status":63,"phases":83,"primaryCompletion":84,"start":85,"enrollment":86,"conditions":87,"interventions":89},"NCT00007774","To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia",[43],"2001-06","1998-03",600,[88,23],"Schizoaffective Disorder",[90,47],"Haloperidol",{"trials":92,"activeCount":8},[],{"intervention":94,"totalTrials":95,"cells":96},"Mirtazapine",2,{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":110,"PHASE3":112,"PHASE4":114,"NA":128},{"trials":98,"activeCount":8},[],{"trials":100,"activeCount":8},[101],{"nctId":102,"briefTitle":103,"status":63,"phases":104,"completion":105,"start":66,"conditions":106,"interventions":108},"NCT00108498","New Pharmacological Treatment for Obstructive Sleep Apnea",[40],"2007-03",[107],"Obstructive Sleep Apnea",[109],"mirtazapine",{"trials":111,"activeCount":8},[],{"trials":113,"activeCount":8},[],{"trials":115,"activeCount":8},[116],{"nctId":117,"briefTitle":118,"status":63,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":127},"NCT00302107","A Placebo-Controlled Study of Mirtazapine for PTSD",[43],"2011-05","2012-06","2006-04",78,[125,126],"Anxiety","PTSD",[94],{"trials":129,"activeCount":8},[],{"intervention":131,"totalTrials":95,"cells":132},"naloxone",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":149,"PHASE4":151,"NA":163},{"trials":134,"activeCount":8},[],{"trials":136,"activeCount":8},[],{"trials":138,"activeCount":8},[139],{"nctId":140,"briefTitle":141,"status":63,"phases":142,"completion":65,"start":66,"conditions":143,"interventions":145},"NCT00108446","Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome",[41],[144],"Irritable Bowel Syndrome",[146,131,147,148],"dextromethorphan","fentanyl","lidocaine",{"trials":150,"activeCount":8},[],{"trials":152,"activeCount":8},[153],{"nctId":154,"briefTitle":155,"status":63,"phases":156,"completion":157,"start":158,"enrollment":86,"conditions":159,"interventions":161},"NCT00007527","Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice",[43],"2002-01","1999-08",[160],"Opiate Dependence",[131,162],"buprenorphine",{"trials":164,"activeCount":8},[],{"intervention":166,"totalTrials":95,"cells":167},"Midodrine",{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":186,"PHASE4":188,"NA":207},{"trials":169,"activeCount":8},[],{"trials":171,"activeCount":8},[],{"trials":173,"activeCount":8},[174],{"nctId":175,"briefTitle":176,"status":63,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},"NCT00835224","Safety and Efficacy of L-NAME and Midodrine to Increase MAP",[41],"2013-06","2013-08","2010-05",34,[183,14],"Orthostatic Hypotension",[185,166],"L-NAME",{"trials":187,"activeCount":8},[],{"trials":189,"activeCount":8},[190],{"nctId":191,"briefTitle":192,"status":63,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":201},"NCT00108355","Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis",[43],"2010-08","2012-08","2003-12",29,[199,200],"Ascites","Cirrhosis",[202,203,166,204,205,206],"Albumin","Intravenous Saline","Oral","Octreotide LAR","Saline",{"trials":208,"activeCount":8},[],{"intervention":210,"totalTrials":211,"cells":212},"Eplerenone",1,{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":235},{"trials":214,"activeCount":8},[],{"trials":216,"activeCount":8},[],{"trials":218,"activeCount":8},[],{"trials":220,"activeCount":8},[],{"trials":222,"activeCount":8},[223],{"nctId":224,"briefTitle":225,"status":63,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":234},"NCT00108251","Aldosterone Antagonism in Diastolic Heart Failure",[43],"2007-09","2007-10","2004-08",48,[232,233],"Congestive Heart Failure","Diastole",[210],{"trials":236,"activeCount":8},[],{"intervention":238,"totalTrials":211,"cells":239},"Oseltamivir",{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":248,"NA":260},{"trials":241,"activeCount":8},[],{"trials":243,"activeCount":8},[],{"trials":245,"activeCount":8},[],{"trials":247,"activeCount":8},[],{"trials":249,"activeCount":8},[250],{"nctId":251,"briefTitle":252,"status":63,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":230,"conditions":256,"interventions":258},"NCT00304434","Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.",[43],"2007-02","2005-02",[257],"Influenza",[238,259],"Probenecid",{"trials":261,"activeCount":8},[],{"intervention":259,"totalTrials":211,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":278},{"trials":265,"activeCount":8},[],{"trials":267,"activeCount":8},[],{"trials":269,"activeCount":8},[],{"trials":271,"activeCount":8},[],{"trials":273,"activeCount":8},[274],{"nctId":251,"briefTitle":252,"status":63,"phases":275,"primaryCompletion":254,"completion":254,"start":255,"enrollment":230,"conditions":276,"interventions":277},[43],[257],[238,259],{"trials":279,"activeCount":8},[],{"intervention":281,"totalTrials":211,"cells":282},"testosterone",{"EARLY_PHASE1":283,"PHASE1":285,"PHASE2":287,"PHASE3":289,"PHASE4":291,"NA":305},{"trials":284,"activeCount":8},[],{"trials":286,"activeCount":8},[],{"trials":288,"activeCount":8},[],{"trials":290,"activeCount":8},[],{"trials":292,"activeCount":8},[293],{"nctId":294,"briefTitle":295,"status":63,"phases":296,"primaryCompletion":297,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":304},"NCT00018356","Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly",[43],"2006-07","2006-08","1999-01",88,[302,303],"Muscle Weakness","Muscular Atrophy",[281],{"trials":306,"activeCount":8},[],{"intervention":308,"totalTrials":211,"cells":309},"Depot naltrexone",{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":331},{"trials":311,"activeCount":8},[],{"trials":313,"activeCount":8},[],{"trials":315,"activeCount":8},[],{"trials":317,"activeCount":8},[],{"trials":319,"activeCount":8},[320],{"nctId":321,"briefTitle":322,"status":323,"phases":324,"primaryCompletion":325,"completion":121,"start":194,"enrollment":326,"conditions":327,"interventions":329},"NCT01155869","Pilot Study of Depot NTX in Homeless Veterans","TERMINATED",[43],"2011-07",7,[328],"Alcohol Dependence",[308,330],"Oral Naltrexone",{"trials":332,"activeCount":8},[],{"intervention":330,"totalTrials":211,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":349},{"trials":336,"activeCount":8},[],{"trials":338,"activeCount":8},[],{"trials":340,"activeCount":8},[],{"trials":342,"activeCount":8},[],{"trials":344,"activeCount":8},[345],{"nctId":321,"briefTitle":322,"status":323,"phases":346,"primaryCompletion":325,"completion":121,"start":194,"enrollment":326,"conditions":347,"interventions":348},[43],[328],[308,330],{"trials":350,"activeCount":8},[],{"intervention":352,"totalTrials":211,"cells":353},"pamidronate",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":373},{"trials":355,"activeCount":8},[],{"trials":357,"activeCount":8},[],{"trials":359,"activeCount":8},[],{"trials":361,"activeCount":8},[],{"trials":363,"activeCount":8},[364],{"nctId":365,"briefTitle":366,"status":63,"phases":367,"completion":227,"start":368,"conditions":369,"interventions":372},"NCT00108394","Osteopenia and Renal Osteodystrophy: Evaluation and Management",[43],"2002-10",[370,371],"Osteopenia","Renal Osteodystrophy",[352],{"trials":374,"activeCount":8},[],{"intervention":162,"totalTrials":211,"cells":376},{"EARLY_PHASE1":377,"PHASE1":379,"PHASE2":381,"PHASE3":383,"PHASE4":385,"NA":391},{"trials":378,"activeCount":8},[],{"trials":380,"activeCount":8},[],{"trials":382,"activeCount":8},[],{"trials":384,"activeCount":8},[],{"trials":386,"activeCount":8},[387],{"nctId":154,"briefTitle":155,"status":63,"phases":388,"completion":157,"start":158,"enrollment":86,"conditions":389,"interventions":390},[43],[160],[131,162],{"trials":392,"activeCount":8},[],{"intervention":202,"totalTrials":211,"cells":394},{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":409},{"trials":396,"activeCount":8},[],{"trials":398,"activeCount":8},[],{"trials":400,"activeCount":8},[],{"trials":402,"activeCount":8},[],{"trials":404,"activeCount":8},[405],{"nctId":191,"briefTitle":192,"status":63,"phases":406,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":407,"interventions":408},[43],[199,200],[202,203,166,204,205,206],{"trials":410,"activeCount":8},[],{"intervention":203,"totalTrials":211,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":421,"NA":427},{"trials":414,"activeCount":8},[],{"trials":416,"activeCount":8},[],{"trials":418,"activeCount":8},[],{"trials":420,"activeCount":8},[],{"trials":422,"activeCount":8},[423],{"nctId":191,"briefTitle":192,"status":63,"phases":424,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":425,"interventions":426},[43],[199,200],[202,203,166,204,205,206],{"trials":428,"activeCount":8},[],{"intervention":204,"totalTrials":211,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":439,"NA":445},{"trials":432,"activeCount":8},[],{"trials":434,"activeCount":8},[],{"trials":436,"activeCount":8},[],{"trials":438,"activeCount":8},[],{"trials":440,"activeCount":8},[441],{"nctId":191,"briefTitle":192,"status":63,"phases":442,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":443,"interventions":444},[43],[199,200],[202,203,166,204,205,206],{"trials":446,"activeCount":8},[],{"intervention":205,"totalTrials":211,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":463},{"trials":450,"activeCount":8},[],{"trials":452,"activeCount":8},[],{"trials":454,"activeCount":8},[],{"trials":456,"activeCount":8},[],{"trials":458,"activeCount":8},[459],{"nctId":191,"briefTitle":192,"status":63,"phases":460,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":461,"interventions":462},[43],[199,200],[202,203,166,204,205,206],{"trials":464,"activeCount":8},[],{"intervention":206,"totalTrials":211,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":481},{"trials":468,"activeCount":8},[],{"trials":470,"activeCount":8},[],{"trials":472,"activeCount":8},[],{"trials":474,"activeCount":8},[],{"trials":476,"activeCount":8},[477],{"nctId":191,"briefTitle":192,"status":63,"phases":478,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":479,"interventions":480},[43],[199,200],[202,203,166,204,205,206],{"trials":482,"activeCount":8},[],{"intervention":484,"totalTrials":211,"cells":485},"Aripiprazole",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":492,"PHASE4":494,"NA":506},{"trials":487,"activeCount":8},[],{"trials":489,"activeCount":8},[],{"trials":491,"activeCount":8},[],{"trials":493,"activeCount":8},[],{"trials":495,"activeCount":8},[496],{"nctId":497,"briefTitle":498,"status":499,"phases":500,"primaryCompletion":501,"completion":501,"start":502,"enrollment":8,"conditions":503,"interventions":505},"NCT00728312","Aripiprazole for Methamphetamine Dependence: Double Blind Placebo Trial","WITHDRAWN",[43],"2010-04","2009-08",[504],"Methamphetamine Dependence",[484],{"trials":507,"activeCount":8},[],{"intervention":509,"totalTrials":211,"cells":510},"Aricept",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":532},{"trials":512,"activeCount":8},[],{"trials":514,"activeCount":8},[],{"trials":516,"activeCount":8},[],{"trials":518,"activeCount":8},[],{"trials":520,"activeCount":8},[521],{"nctId":522,"briefTitle":523,"status":63,"phases":524,"completion":525,"start":526,"conditions":527,"interventions":529},"NCT00018278","Electrophysiologic Measures of Treatment Response in Alzheimer Disease",[43],"2001-09","1998-10",[528],"Alzheimer Disease",[509,530,531],"Exelon","Nicoderm Patch",{"trials":533,"activeCount":8},[],{"intervention":530,"totalTrials":211,"cells":535},{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":550},{"trials":537,"activeCount":8},[],{"trials":539,"activeCount":8},[],{"trials":541,"activeCount":8},[],{"trials":543,"activeCount":8},[],{"trials":545,"activeCount":8},[546],{"nctId":522,"briefTitle":523,"status":63,"phases":547,"completion":525,"start":526,"conditions":548,"interventions":549},[43],[528],[509,530,531],{"trials":551,"activeCount":8},[],{"intervention":531,"totalTrials":211,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":568},{"trials":555,"activeCount":8},[],{"trials":557,"activeCount":8},[],{"trials":559,"activeCount":8},[],{"trials":561,"activeCount":8},[],{"trials":563,"activeCount":8},[564],{"nctId":522,"briefTitle":523,"status":63,"phases":565,"completion":525,"start":526,"conditions":566,"interventions":567},[43],[528],[509,530,531],{"trials":569,"activeCount":8},[],{"intervention":571,"totalTrials":211,"cells":572},"Metformin",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":594},{"trials":574,"activeCount":8},[],{"trials":576,"activeCount":8},[],{"trials":578,"activeCount":8},[],{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[583],{"nctId":584,"briefTitle":585,"status":63,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":230,"conditions":590,"interventions":592},"NCT00108615","Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance",[43],"2007-04","2007-12","2004-01",[591,26],"Glucose Metabolism Disorders",[571,593,571,593],"Pioglitazone",{"trials":595,"activeCount":8},[],{"intervention":593,"totalTrials":211,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":612},{"trials":599,"activeCount":8},[],{"trials":601,"activeCount":8},[],{"trials":603,"activeCount":8},[],{"trials":605,"activeCount":8},[],{"trials":607,"activeCount":8},[608],{"nctId":584,"briefTitle":585,"status":63,"phases":609,"primaryCompletion":587,"completion":588,"start":589,"enrollment":230,"conditions":610,"interventions":611},[43],[591,26],[571,593,571,593],{"trials":613,"activeCount":8},[],{"intervention":615,"totalTrials":211,"cells":616},"NALTREXONE",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":637},{"trials":618,"activeCount":8},[],{"trials":620,"activeCount":8},[],{"trials":622,"activeCount":8},[],{"trials":624,"activeCount":8},[],{"trials":626,"activeCount":8},[627],{"nctId":628,"briefTitle":629,"status":63,"phases":630,"primaryCompletion":631,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":636},"NCT00018824","Treating Alcohol Use In Older Adults With Depression",[43],"2005-01","1999-10",74,[635,17],"Alcoholism",[615],{"trials":638,"activeCount":8},[],{"intervention":640,"totalTrials":211,"cells":641},"Ramelteon",{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":664},{"trials":643,"activeCount":8},[],{"trials":645,"activeCount":8},[],{"trials":647,"activeCount":8},[],{"trials":649,"activeCount":8},[],{"trials":651,"activeCount":8},[652],{"nctId":653,"briefTitle":654,"status":63,"phases":655,"primaryCompletion":656,"completion":325,"start":657,"enrollment":658,"conditions":659,"interventions":663},"NCT00507546","Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia",[43],"2010-12","2007-07",12,[660,14,661,662],"Insomnia","Tetraplegia","Sleep Disorders",[640],{"trials":665,"activeCount":8},[],{"intervention":667,"totalTrials":211,"cells":668},"Neostigmine",{"EARLY_PHASE1":669,"PHASE1":671,"PHASE2":673,"PHASE3":675,"PHASE4":677,"NA":689},{"trials":670,"activeCount":8},[],{"trials":672,"activeCount":8},[],{"trials":674,"activeCount":8},[],{"trials":676,"activeCount":8},[],{"trials":678,"activeCount":8},[679],{"nctId":680,"briefTitle":681,"status":63,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":688},"NCT00745095","Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage",[43],"2013-03","2013-05","2009-03",360,[14],[667],{"trials":690,"activeCount":8},[],{"intervention":692,"totalTrials":211,"cells":693},"Citalopram or Placebo",{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":700,"PHASE4":702,"NA":712},{"trials":695,"activeCount":8},[],{"trials":697,"activeCount":8},[],{"trials":699,"activeCount":8},[],{"trials":701,"activeCount":8},[],{"trials":703,"activeCount":8},[704],{"nctId":705,"briefTitle":706,"status":63,"phases":707,"completion":708,"start":66,"conditions":709,"interventions":711},"NCT00108563","VISN 20: Prophylactic Treatment of Interferon-Induced Depression in Hepatitis C Patients",[43],"2006-09",[710,17],"Hepatitis C",[692],{"trials":713,"activeCount":8},[],{"intervention":715,"totalTrials":211,"cells":716},"Mupirocin Ointment [Treatment]",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":737},{"trials":718,"activeCount":8},[],{"trials":720,"activeCount":8},[],{"trials":722,"activeCount":8},[],{"trials":724,"activeCount":8},[],{"trials":726,"activeCount":8},[727],{"nctId":728,"briefTitle":729,"status":63,"phases":730,"primaryCompletion":195,"completion":195,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT00108160","Preventing Staphylococcal (Staph) Infection",[43],"2005-04",146,[734],"Staphylococcal Infections",[715,736],"Polyethylene Glycol Ointment [Placebo]",{"trials":738,"activeCount":8},[],{"intervention":736,"totalTrials":211,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":747,"PHASE4":749,"NA":755},{"trials":742,"activeCount":8},[],{"trials":744,"activeCount":8},[],{"trials":746,"activeCount":8},[],{"trials":748,"activeCount":8},[],{"trials":750,"activeCount":8},[751],{"nctId":728,"briefTitle":729,"status":63,"phases":752,"primaryCompletion":195,"completion":195,"start":731,"enrollment":732,"conditions":753,"interventions":754},[43],[734],[715,736],{"trials":756,"activeCount":8},[],{"intervention":758,"totalTrials":211,"cells":759},"Estradiol followed by progesterone",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":780},{"trials":761,"activeCount":8},[],{"trials":763,"activeCount":8},[],{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[],{"trials":769,"activeCount":8},[770],{"nctId":771,"briefTitle":772,"status":63,"phases":773,"completion":774,"start":775,"conditions":776,"interventions":778},"NCT00108238","Estrogen Alternatives Study",[43],"2006-12","2003-04",[777],"Healthy",[758,779],"Raloxifene",{"trials":781,"activeCount":8},[],{"intervention":779,"totalTrials":211,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":798},{"trials":785,"activeCount":8},[],{"trials":787,"activeCount":8},[],{"trials":789,"activeCount":8},[],{"trials":791,"activeCount":8},[],{"trials":793,"activeCount":8},[794],{"nctId":771,"briefTitle":772,"status":63,"phases":795,"completion":774,"start":775,"conditions":796,"interventions":797},[43],[777],[758,779],{"trials":799,"activeCount":8},[],{"intervention":801,"totalTrials":211,"cells":802},"5HTP",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":821},{"trials":804,"activeCount":8},[],{"trials":806,"activeCount":8},[],{"trials":808,"activeCount":8},[],{"trials":810,"activeCount":8},[],{"trials":812,"activeCount":8},[813],{"nctId":814,"briefTitle":815,"status":63,"phases":816,"primaryCompletion":196,"completion":196,"start":817,"conditions":818,"interventions":819},"NCT00100464","Serotonin and the Upper Airway in Obstructive Sleep Apnea",[43],"2000-11",[107],[820,801],"Paroxetine",{"trials":822,"activeCount":8},[],{"intervention":824,"totalTrials":95,"cells":825},"celecoxib",{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":841,"PHASE3":843,"PHASE4":858,"NA":860},{"trials":827,"activeCount":8},[],{"trials":829,"activeCount":8},[830],{"nctId":831,"briefTitle":832,"status":499,"phases":833,"primaryCompletion":834,"completion":835,"start":836,"enrollment":8,"conditions":837,"interventions":839},"NCT00108186","Celecoxib Treatment for Lung Cancer",[40],"2010-06","2011-06","2004-10",[838],"Non-Small-Cell Lung Carcinoma",[840],"Celecoxib",{"trials":842,"activeCount":8},[],{"trials":844,"activeCount":8},[845],{"nctId":846,"briefTitle":847,"status":63,"phases":848,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":854},"NCT00032890","Glucosamine\u002FChondroitin Arthritis Intervention Trial (GAIT)",[42],"2004-02","2000-04",1588,[853],"Osteoarthritis",[855,856,857,824],"glucosamine","chondroitin sulfate","glucosamine and chondroitin sulfate combined",{"trials":859,"activeCount":8},[],{"trials":861,"activeCount":8},[],{"intervention":863,"totalTrials":211,"cells":864},"extended release beta-2 adrenergic agonist",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":881,"NA":883},{"trials":866,"activeCount":8},[],{"trials":868,"activeCount":8},[],{"trials":870,"activeCount":8},[],{"trials":872,"activeCount":8},[873],{"nctId":874,"briefTitle":875,"status":63,"phases":876,"primaryCompletion":195,"completion":877,"start":587,"enrollment":878,"conditions":879,"interventions":880},"NCT00755079","Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury",[41,42],"2014-12",40,[14],[863],{"trials":882,"activeCount":8},[],{"trials":884,"activeCount":8},[],{"intervention":886,"totalTrials":211,"cells":887},"alpha-lipoic acid",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":907,"NA":909},{"trials":889,"activeCount":8},[],{"trials":891,"activeCount":8},[],{"trials":893,"activeCount":8},[],{"trials":895,"activeCount":8},[896],{"nctId":897,"briefTitle":898,"status":63,"phases":899,"primaryCompletion":900,"completion":835,"start":228,"enrollment":901,"conditions":902,"interventions":905},"NCT00477607","Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin",[41,42],"2011-03",39,[903,904],"Ototoxicity","Unspecified Adult Solid Tumor",[886,906],"laboratory biomarker analysis",{"trials":908,"activeCount":8},[],{"trials":910,"activeCount":8},[],{"intervention":906,"totalTrials":211,"cells":912},{"EARLY_PHASE1":913,"PHASE1":915,"PHASE2":917,"PHASE3":919,"PHASE4":925,"NA":927},{"trials":914,"activeCount":8},[],{"trials":916,"activeCount":8},[],{"trials":918,"activeCount":8},[],{"trials":920,"activeCount":8},[921],{"nctId":897,"briefTitle":898,"status":63,"phases":922,"primaryCompletion":900,"completion":835,"start":228,"enrollment":901,"conditions":923,"interventions":924},[41,42],[903,904],[886,906],{"trials":926,"activeCount":8},[],{"trials":928,"activeCount":8},[],{"intervention":930,"totalTrials":211,"cells":931},"Psyllium powder",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":938,"PHASE4":952,"NA":954},{"trials":933,"activeCount":8},[],{"trials":935,"activeCount":8},[],{"trials":937,"activeCount":8},[],{"trials":939,"activeCount":8},[940],{"nctId":941,"briefTitle":942,"status":63,"phases":943,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":948,"interventions":950},"NCT00727649","Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence",[41,42],"2013-10","2013-12","2008-07",80,[949],"Fecal Incontinence",[930,951],"Loperamide",{"trials":953,"activeCount":8},[],{"trials":955,"activeCount":8},[],{"intervention":951,"totalTrials":211,"cells":957},{"EARLY_PHASE1":958,"PHASE1":960,"PHASE2":962,"PHASE3":964,"PHASE4":970,"NA":972},{"trials":959,"activeCount":8},[],{"trials":961,"activeCount":8},[],{"trials":963,"activeCount":8},[],{"trials":965,"activeCount":8},[966],{"nctId":941,"briefTitle":942,"status":63,"phases":967,"primaryCompletion":944,"completion":945,"start":946,"enrollment":947,"conditions":968,"interventions":969},[41,42],[949],[930,951],{"trials":971,"activeCount":8},[],{"trials":973,"activeCount":8},[],{"intervention":975,"totalTrials":211,"cells":976},"Stepped care",{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":995,"NA":997},{"trials":978,"activeCount":8},[],{"trials":980,"activeCount":8},[],{"trials":982,"activeCount":8},[],{"trials":984,"activeCount":8},[985],{"nctId":986,"briefTitle":987,"status":63,"phases":988,"primaryCompletion":178,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":994},"NCT00926588","Stepped Care to Optimize Pain Care Effectiveness",[42],"2015-06","2009-10",250,[993],"Pain",[975],{"trials":996,"activeCount":8},[],{"trials":998,"activeCount":8},[],{"intervention":1000,"totalTrials":211,"cells":1001},"Doxycycline (200mg\u002Fday) or Placebo",{"EARLY_PHASE1":1002,"PHASE1":1004,"PHASE2":1006,"PHASE3":1008,"PHASE4":1020,"NA":1022},{"trials":1003,"activeCount":8},[],{"trials":1005,"activeCount":8},[],{"trials":1007,"activeCount":8},[],{"trials":1009,"activeCount":8},[1010],{"nctId":1011,"briefTitle":1012,"status":63,"phases":1013,"completion":1014,"start":299,"enrollment":1015,"conditions":1016,"interventions":1019},"NCT00007735","Antibiotic Treatment of Gulf War Veterans' Illnesses",[42],"2001-10",450,[1017,1018],"Persian Gulf Syndrome","Mycoplasma Infections",[1000],{"trials":1021,"activeCount":8},[],{"trials":1023,"activeCount":8},[],{"intervention":1025,"totalTrials":211,"cells":1026},"Tretinoin 0.1% cream or placebo",{"EARLY_PHASE1":1027,"PHASE1":1029,"PHASE2":1031,"PHASE3":1033,"PHASE4":1046,"NA":1048},{"trials":1028,"activeCount":8},[],{"trials":1030,"activeCount":8},[],{"trials":1032,"activeCount":8},[],{"trials":1034,"activeCount":8},[1035],{"nctId":1036,"briefTitle":1037,"status":63,"phases":1038,"primaryCompletion":1039,"completion":297,"start":85,"enrollment":1040,"conditions":1041,"interventions":1045},"NCT00007631","Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer",[42],"2004-11",1131,[1042,1043,1044],"Carcinoma, Basal Cell","Carcinoma, Squamous Cell","Skin Neoplasms",[1025],{"trials":1047,"activeCount":8},[],{"trials":1049,"activeCount":8},[],{"intervention":1051,"totalTrials":211,"cells":1052},"Rabeprazole 20mg, placebo dinner and bedtime",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1072,"NA":1074},{"trials":1054,"activeCount":8},[],{"trials":1056,"activeCount":8},[],{"trials":1058,"activeCount":8},[],{"trials":1060,"activeCount":8},[1061],{"nctId":1062,"briefTitle":1063,"status":63,"phases":1064,"primaryCompletion":501,"completion":1065,"start":122,"enrollment":1066,"conditions":1067,"interventions":1069},"NCT00539240","Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI",[41,42],"2011-11",236,[1068],"Gastroesophageal Reflux Disease",[1051,1070,1071],"Rabeprazole 20 mg two times, Placebo at bedtime","Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant",{"trials":1073,"activeCount":8},[],{"trials":1075,"activeCount":8},[],{"intervention":1070,"totalTrials":211,"cells":1077},{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1090,"NA":1092},{"trials":1079,"activeCount":8},[],{"trials":1081,"activeCount":8},[],{"trials":1083,"activeCount":8},[],{"trials":1085,"activeCount":8},[1086],{"nctId":1062,"briefTitle":1063,"status":63,"phases":1087,"primaryCompletion":501,"completion":1065,"start":122,"enrollment":1066,"conditions":1088,"interventions":1089},[41,42],[1068],[1051,1070,1071],{"trials":1091,"activeCount":8},[],{"trials":1093,"activeCount":8},[],{"intervention":1071,"totalTrials":211,"cells":1095},{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1100,"PHASE3":1102,"PHASE4":1108,"NA":1110},{"trials":1097,"activeCount":8},[],{"trials":1099,"activeCount":8},[],{"trials":1101,"activeCount":8},[],{"trials":1103,"activeCount":8},[1104],{"nctId":1062,"briefTitle":1063,"status":63,"phases":1105,"primaryCompletion":501,"completion":1065,"start":122,"enrollment":1066,"conditions":1106,"interventions":1107},[41,42],[1068],[1051,1070,1071],{"trials":1109,"activeCount":8},[],{"trials":1111,"activeCount":8},[],{"intervention":1113,"totalTrials":211,"cells":1114},"S-adenosylmethionine",{"EARLY_PHASE1":1115,"PHASE1":1117,"PHASE2":1119,"PHASE3":1121,"PHASE4":1130,"NA":1132},{"trials":1116,"activeCount":8},[],{"trials":1118,"activeCount":8},[],{"trials":1120,"activeCount":8},[],{"trials":1122,"activeCount":8},[1123],{"nctId":1124,"briefTitle":1125,"status":63,"phases":1126,"completion":774,"start":589,"conditions":1127,"interventions":1129},"NCT00108589","S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis",[42],[1128],"Hepatitis",[1113],{"trials":1131,"activeCount":8},[],{"trials":1133,"activeCount":8},[],{"intervention":855,"totalTrials":211,"cells":1135},{"EARLY_PHASE1":1136,"PHASE1":1138,"PHASE2":1140,"PHASE3":1142,"PHASE4":1148,"NA":1150},{"trials":1137,"activeCount":8},[],{"trials":1139,"activeCount":8},[],{"trials":1141,"activeCount":8},[],{"trials":1143,"activeCount":8},[1144],{"nctId":846,"briefTitle":847,"status":63,"phases":1145,"completion":849,"start":850,"enrollment":851,"conditions":1146,"interventions":1147},[42],[853],[855,856,857,824],{"trials":1149,"activeCount":8},[],{"trials":1151,"activeCount":8},[],{"intervention":856,"totalTrials":211,"cells":1153},{"EARLY_PHASE1":1154,"PHASE1":1156,"PHASE2":1158,"PHASE3":1160,"PHASE4":1166,"NA":1168},{"trials":1155,"activeCount":8},[],{"trials":1157,"activeCount":8},[],{"trials":1159,"activeCount":8},[],{"trials":1161,"activeCount":8},[1162],{"nctId":846,"briefTitle":847,"status":63,"phases":1163,"completion":849,"start":850,"enrollment":851,"conditions":1164,"interventions":1165},[42],[853],[855,856,857,824],{"trials":1167,"activeCount":8},[],{"trials":1169,"activeCount":8},[],{"intervention":857,"totalTrials":211,"cells":1171},{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1178,"PHASE4":1184,"NA":1186},{"trials":1173,"activeCount":8},[],{"trials":1175,"activeCount":8},[],{"trials":1177,"activeCount":8},[],{"trials":1179,"activeCount":8},[1180],{"nctId":846,"briefTitle":847,"status":63,"phases":1181,"completion":849,"start":850,"enrollment":851,"conditions":1182,"interventions":1183},[42],[853],[855,856,857,824],{"trials":1185,"activeCount":8},[],{"trials":1187,"activeCount":8},[],{"intervention":1189,"totalTrials":211,"cells":1190},"losartan",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1212,"NA":1214},{"trials":1192,"activeCount":8},[],{"trials":1194,"activeCount":8},[],{"trials":1196,"activeCount":8},[],{"trials":1198,"activeCount":8},[1199],{"nctId":1200,"briefTitle":1201,"status":323,"phases":1202,"primaryCompletion":1203,"completion":1204,"start":946,"enrollment":1205,"conditions":1206,"interventions":1210},"NCT00555217","VA NEPHRON-D: Diabetes iN Nephropathy Study",[42],"2014-09","2014-10",1448,[1207,1208,1209],"Kidney Disease","Nephropathy","Type 2 Diabetes",[1189,1211],"lisinopril",{"trials":1213,"activeCount":8},[],{"trials":1215,"activeCount":8},[],{"intervention":1211,"totalTrials":211,"cells":1217},{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1222,"PHASE3":1224,"PHASE4":1230,"NA":1232},{"trials":1219,"activeCount":8},[],{"trials":1221,"activeCount":8},[],{"trials":1223,"activeCount":8},[],{"trials":1225,"activeCount":8},[1226],{"nctId":1200,"briefTitle":1201,"status":323,"phases":1227,"primaryCompletion":1203,"completion":1204,"start":946,"enrollment":1205,"conditions":1228,"interventions":1229},[42],[1207,1208,1209],[1189,1211],{"trials":1231,"activeCount":8},[],{"trials":1233,"activeCount":8},[],{"intervention":1235,"totalTrials":211,"cells":1236},"PAL-40 Active",{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1256,"NA":1258},{"trials":1238,"activeCount":8},[],{"trials":1240,"activeCount":8},[],{"trials":1242,"activeCount":8},[],{"trials":1244,"activeCount":8},[1245],{"nctId":1246,"briefTitle":1247,"status":63,"phases":1248,"primaryCompletion":298,"completion":708,"start":1249,"enrollment":1250,"conditions":1251,"interventions":1254},"NCT00032435","Homocysteine Study (HOST)",[42],"2001-05",2003,[1252,1253],"End Stage Renal Disease","Renal Failure",[1235,1255],"PAL-40 Placebo",{"trials":1257,"activeCount":8},[],{"trials":1259,"activeCount":8},[],{"intervention":1255,"totalTrials":211,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":8},[],{"trials":1265,"activeCount":8},[],{"trials":1267,"activeCount":8},[],{"trials":1269,"activeCount":8},[1270],{"nctId":1246,"briefTitle":1247,"status":63,"phases":1271,"primaryCompletion":298,"completion":708,"start":1249,"enrollment":1250,"conditions":1272,"interventions":1273},[42],[1252,1253],[1235,1255],{"trials":1275,"activeCount":8},[],{"trials":1277,"activeCount":8},[],{"intervention":1279,"totalTrials":211,"cells":1280},"Lofexidine",{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1287,"PHASE4":1298,"NA":1300},{"trials":1282,"activeCount":8},[],{"trials":1284,"activeCount":8},[],{"trials":1286,"activeCount":8},[],{"trials":1288,"activeCount":8},[1289],{"nctId":1290,"briefTitle":1291,"status":63,"phases":1292,"primaryCompletion":228,"completion":228,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1297},"NCT00235729","Lofexidine for Inpatient Opiate Detox",[42],"2006-06",264,[1296],"Opiate Addiction",[1279],{"trials":1299,"activeCount":8},[],{"trials":1301,"activeCount":8},[],{"intervention":1303,"totalTrials":211,"cells":1304},"Carbamazepine",{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1311,"PHASE4":1325,"NA":1327},{"trials":1306,"activeCount":8},[],{"trials":1308,"activeCount":8},[],{"trials":1310,"activeCount":8},[],{"trials":1312,"activeCount":8},[1313],{"nctId":1314,"briefTitle":1315,"status":63,"phases":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1322},"NCT00007670","Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.",[42],"2003-03","1998-01",720,[1321],"Seizures",[1303,1323,1324],"Gabapentin","Lamotrigine",{"trials":1326,"activeCount":8},[],{"trials":1328,"activeCount":8},[],{"intervention":1324,"totalTrials":211,"cells":1330},{"EARLY_PHASE1":1331,"PHASE1":1333,"PHASE2":1335,"PHASE3":1337,"PHASE4":1343,"NA":1345},{"trials":1332,"activeCount":8},[],{"trials":1334,"activeCount":8},[],{"trials":1336,"activeCount":8},[],{"trials":1338,"activeCount":8},[1339],{"nctId":1314,"briefTitle":1315,"status":63,"phases":1340,"completion":1317,"start":1318,"enrollment":1319,"conditions":1341,"interventions":1342},[42],[1321],[1303,1323,1324],{"trials":1344,"activeCount":8},[],{"trials":1346,"activeCount":8},[],{"intervention":1348,"totalTrials":211,"cells":1349},"Warfarin titrated to an INR of 2.5-3.0",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1370,"NA":1372},{"trials":1351,"activeCount":8},[],{"trials":1353,"activeCount":8},[],{"trials":1355,"activeCount":8},[],{"trials":1357,"activeCount":8},[1358],{"nctId":1359,"briefTitle":1360,"status":63,"phases":1361,"primaryCompletion":1362,"completion":1363,"start":526,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT00007683","Warfarin and Antiplatelet Therapy in Chronic Heart Failure",[42],"2003-07","2004-12",1587,[1366],"Heart Failure",[1348,1368,1369],"Aspirin","Clopidogrel 75",{"trials":1371,"activeCount":8},[],{"trials":1373,"activeCount":8},[],{"intervention":1368,"totalTrials":211,"cells":1375},{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1388,"NA":1390},{"trials":1377,"activeCount":8},[],{"trials":1379,"activeCount":8},[],{"trials":1381,"activeCount":8},[],{"trials":1383,"activeCount":8},[1384],{"nctId":1359,"briefTitle":1360,"status":63,"phases":1385,"primaryCompletion":1362,"completion":1363,"start":526,"enrollment":1364,"conditions":1386,"interventions":1387},[42],[1366],[1348,1368,1369],{"trials":1389,"activeCount":8},[],{"trials":1391,"activeCount":8},[],{"intervention":1369,"totalTrials":211,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1406,"NA":1408},{"trials":1395,"activeCount":8},[],{"trials":1397,"activeCount":8},[],{"trials":1399,"activeCount":8},[],{"trials":1401,"activeCount":8},[1402],{"nctId":1359,"briefTitle":1360,"status":63,"phases":1403,"primaryCompletion":1362,"completion":1363,"start":526,"enrollment":1364,"conditions":1404,"interventions":1405},[42],[1366],[1348,1368,1369],{"trials":1407,"activeCount":8},[],{"trials":1409,"activeCount":8},[],{"intervention":1411,"totalTrials":211,"cells":1412},"bupropion and transdermal patch",{"EARLY_PHASE1":1413,"PHASE1":1415,"PHASE2":1417,"PHASE3":1419,"PHASE4":1430,"NA":1432},{"trials":1414,"activeCount":8},[],{"trials":1416,"activeCount":8},[],{"trials":1418,"activeCount":8},[],{"trials":1420,"activeCount":8},[1421],{"nctId":1422,"briefTitle":1423,"status":63,"phases":1424,"completion":1425,"start":66,"conditions":1426,"interventions":1428},"NCT00108537","Non-Nicotine Agents for Smoking Cessation",[42],"2005-09",[1427],"Tobacco Use Disorder",[1411,1429],"transdermal patch and nicotine inhaler",{"trials":1431,"activeCount":8},[],{"trials":1433,"activeCount":8},[],{"intervention":1429,"totalTrials":211,"cells":1435},{"EARLY_PHASE1":1436,"PHASE1":1438,"PHASE2":1440,"PHASE3":1442,"PHASE4":1448,"NA":1450},{"trials":1437,"activeCount":8},[],{"trials":1439,"activeCount":8},[],{"trials":1441,"activeCount":8},[],{"trials":1443,"activeCount":8},[1444],{"nctId":1422,"briefTitle":1423,"status":63,"phases":1445,"completion":1425,"start":66,"conditions":1446,"interventions":1447},[42],[1427],[1411,1429],{"trials":1449,"activeCount":8},[],{"trials":1451,"activeCount":8},[],{"intervention":1453,"totalTrials":211,"cells":1454},"Oxybutynin chloride, extended-release",{"EARLY_PHASE1":1455,"PHASE1":1457,"PHASE2":1459,"PHASE3":1461,"PHASE4":1471,"NA":1473},{"trials":1456,"activeCount":8},[],{"trials":1458,"activeCount":8},[],{"trials":1460,"activeCount":8},[],{"trials":1462,"activeCount":8},[1463],{"nctId":1464,"briefTitle":1465,"status":63,"phases":1466,"primaryCompletion":990,"completion":990,"start":631,"enrollment":1467,"conditions":1468,"interventions":1470},"NCT01187498","Behavioral Treatment of Overactive Bladder in Men",[42],143,[1469],"Overactive Bladder",[1453],{"trials":1472,"activeCount":8},[],{"trials":1474,"activeCount":8},[],{"intervention":1476,"totalTrials":211,"cells":1477},"IM risperidone",{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1484,"PHASE4":1495,"NA":1497},{"trials":1479,"activeCount":8},[],{"trials":1481,"activeCount":8},[],{"trials":1483,"activeCount":8},[],{"trials":1485,"activeCount":8},[1486],{"nctId":1487,"briefTitle":1488,"status":63,"phases":1489,"primaryCompletion":1490,"completion":1490,"start":708,"enrollment":1491,"conditions":1492,"interventions":1493},"NCT00132314","Long-Acting Injectable Risperidone in the Treatment of Schizophrenia",[42],"2009-09",382,[88,23],[1476,1494],"oral antipsychotic medication",{"trials":1496,"activeCount":8},[],{"trials":1498,"activeCount":8},[],{"intervention":1494,"totalTrials":211,"cells":1500},{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1507,"PHASE4":1513,"NA":1515},{"trials":1502,"activeCount":8},[],{"trials":1504,"activeCount":8},[],{"trials":1506,"activeCount":8},[],{"trials":1508,"activeCount":8},[1509],{"nctId":1487,"briefTitle":1488,"status":63,"phases":1510,"primaryCompletion":1490,"completion":1490,"start":708,"enrollment":1491,"conditions":1511,"interventions":1512},[42],[88,23],[1476,1494],{"trials":1514,"activeCount":8},[],{"trials":1516,"activeCount":8},[],{"intervention":1518,"totalTrials":211,"cells":1519},"Amiodarone",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1524,"PHASE3":1526,"PHASE4":1540,"NA":1542},{"trials":1521,"activeCount":8},[],{"trials":1523,"activeCount":8},[],{"trials":1525,"activeCount":8},[],{"trials":1527,"activeCount":8},[1528],{"nctId":1529,"briefTitle":1530,"status":63,"phases":1531,"primaryCompletion":368,"completion":196,"start":1532,"enrollment":1533,"conditions":1534,"interventions":1538},"NCT00007605","Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm",[42],"1998-04",706,[1535,1536,1537],"Atrial Fibrillation","Cerebrovascular Accident","Death, Sudden",[1518,1539],"Sotalol",{"trials":1541,"activeCount":8},[],{"trials":1543,"activeCount":8},[],{"intervention":1539,"totalTrials":211,"cells":1545},{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1558,"NA":1560},{"trials":1547,"activeCount":8},[],{"trials":1549,"activeCount":8},[],{"trials":1551,"activeCount":8},[],{"trials":1553,"activeCount":8},[1554],{"nctId":1529,"briefTitle":1530,"status":63,"phases":1555,"primaryCompletion":368,"completion":196,"start":1532,"enrollment":1533,"conditions":1556,"interventions":1557},[42],[1535,1536,1537],[1518,1539],{"trials":1559,"activeCount":8},[],{"trials":1561,"activeCount":8},[],{"intervention":1563,"totalTrials":211,"cells":1564},"treatments for essential tremor",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1571,"PHASE4":1581,"NA":1583},{"trials":1566,"activeCount":8},[],{"trials":1568,"activeCount":8},[],{"trials":1570,"activeCount":8},[],{"trials":1572,"activeCount":8},[1573],{"nctId":1574,"briefTitle":1575,"status":63,"phases":1576,"completion":1577,"start":76,"conditions":1578,"interventions":1580},"NCT00018564","Novel Therapies for Essential Tremor",[42],"2003-09",[1579],"Essential Tremor",[1563],{"trials":1582,"activeCount":8},[],{"trials":1584,"activeCount":8},[],{"intervention":1586,"totalTrials":211,"cells":1587},"dl-alpha-tocopherol",{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1594,"PHASE4":1608,"NA":1610},{"trials":1589,"activeCount":8},[],{"trials":1591,"activeCount":8},[],{"trials":1593,"activeCount":8},[],{"trials":1595,"activeCount":8},[1596],{"nctId":1597,"briefTitle":1598,"status":63,"phases":1599,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":1604,"interventions":1606},"NCT00235716","A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease",[42],"2012-09","2012-10","2007-08",613,[1605],"Alzheimer's Disease",[1586,1607,1586,1607],"Memantine",{"trials":1609,"activeCount":8},[],{"trials":1611,"activeCount":8},[],{"intervention":1607,"totalTrials":211,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1618,"PHASE3":1620,"PHASE4":1626,"NA":1628},{"trials":1615,"activeCount":8},[],{"trials":1617,"activeCount":8},[],{"trials":1619,"activeCount":8},[],{"trials":1621,"activeCount":8},[1622],{"nctId":1597,"briefTitle":1598,"status":63,"phases":1623,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":1624,"interventions":1625},[42],[1605],[1586,1607,1586,1607],{"trials":1627,"activeCount":8},[],{"trials":1629,"activeCount":8},[],{"intervention":1631,"totalTrials":211,"cells":1632},"Varicella-zoster vaccine",{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1639,"PHASE4":1653,"NA":1655},{"trials":1634,"activeCount":8},[],{"trials":1636,"activeCount":8},[],{"trials":1638,"activeCount":8},[],{"trials":1640,"activeCount":8},[1641],{"nctId":1642,"briefTitle":1643,"status":63,"phases":1644,"primaryCompletion":1645,"completion":1646,"start":1647,"enrollment":1648,"conditions":1649,"interventions":1652},"NCT00007501","Shingles Prevention Study",[42],"2004-04","2011-02","1998-11",38456,[1650,1651],"Herpes Zoster","Postherpetic Neuralgia",[1631],{"trials":1654,"activeCount":8},[],{"trials":1656,"activeCount":8},[],{"intervention":1658,"totalTrials":211,"cells":1659},"N-Nitro L-arginine-methylester",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1677,"NA":1679},{"trials":1661,"activeCount":8},[],{"trials":1663,"activeCount":8},[],{"trials":1665,"activeCount":8},[],{"trials":1667,"activeCount":8},[1668],{"nctId":1669,"briefTitle":1670,"status":63,"phases":1671,"primaryCompletion":834,"completion":834,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1676},"NCT00237770","Prevention of Low Blood Pressure in Persons With Tetraplegia",[41,42],"2003-06",16,[1675,14],"Hypotension",[1658],{"trials":1678,"activeCount":8},[],{"trials":1680,"activeCount":8},[],{"intervention":1682,"totalTrials":95,"cells":1683},"Mecamylamine",{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1697,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1685,"activeCount":8},[],{"trials":1687,"activeCount":8},[1688],{"nctId":1689,"briefTitle":1690,"status":63,"phases":1691,"completion":84,"start":1647,"conditions":1692,"interventions":1694},"NCT00018187","Combinations of Pharmacologic Smoking Cessation Treatments",[40],[1693],"Smoking",[1695,1682,1696],"Bupropion","Nicotine Patch",{"trials":1698,"activeCount":8},[1699],{"nctId":1700,"briefTitle":1701,"status":63,"phases":1702,"completion":84,"start":1703,"conditions":1704,"interventions":1705},"NCT00018161","Treatment to Quit Smoking",[41],"1997-01",[1693],[1682,1696],{"trials":1707,"activeCount":8},[],{"trials":1709,"activeCount":8},[],{"trials":1711,"activeCount":8},[],{"intervention":1696,"totalTrials":95,"cells":1713},{"EARLY_PHASE1":1714,"PHASE1":1716,"PHASE2":1722,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1715,"activeCount":8},[],{"trials":1717,"activeCount":8},[1718],{"nctId":1689,"briefTitle":1690,"status":63,"phases":1719,"completion":84,"start":1647,"conditions":1720,"interventions":1721},[40],[1693],[1695,1682,1696],{"trials":1723,"activeCount":8},[1724],{"nctId":1700,"briefTitle":1701,"status":63,"phases":1725,"completion":84,"start":1703,"conditions":1726,"interventions":1727},[41],[1693],[1682,1696],{"trials":1729,"activeCount":8},[],{"trials":1731,"activeCount":8},[],{"trials":1733,"activeCount":8},[],{"intervention":148,"totalTrials":95,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1737,"activeCount":8},[],{"trials":1739,"activeCount":8},[],{"trials":1741,"activeCount":8},[1742,1746],{"nctId":140,"briefTitle":141,"status":63,"phases":1743,"completion":65,"start":66,"conditions":1744,"interventions":1745},[41],[144],[146,131,147,148],{"nctId":1747,"briefTitle":1748,"status":499,"phases":1749,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":8,"conditions":1752,"interventions":1753},"NCT00907829","Source of Hand Weakness After Stroke",[41],"2013-01","2009-02",[20,1536],[148],{"trials":1755,"activeCount":8},[],{"trials":1757,"activeCount":8},[],{"trials":1759,"activeCount":8},[],{"intervention":1761,"totalTrials":211,"cells":1762},"acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN",{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1780,"PHASE4":1782,"NA":1784},{"trials":1764,"activeCount":8},[],{"trials":1766,"activeCount":8},[],{"trials":1768,"activeCount":8},[1769],{"nctId":1770,"briefTitle":1771,"status":63,"phases":1772,"completion":1773,"enrollment":1774,"conditions":1775,"interventions":1779},"NCT00012857","Pain Management and Behavioral Outcomes in Patients With Dementia",[41],"2001-03",66,[1776,1777,1778],"Dementia","Alzheimer Disease, Pain","Behavior, Agitation",[1761],{"trials":1781,"activeCount":8},[],{"trials":1783,"activeCount":8},[],{"trials":1785,"activeCount":8},[],{"intervention":1787,"totalTrials":211,"cells":1788},"D-cycloserine + distributed treatment",{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1793,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1790,"activeCount":8},[],{"trials":1792,"activeCount":8},[],{"trials":1794,"activeCount":8},[1795],{"nctId":1796,"briefTitle":1797,"status":63,"phases":1798,"primaryCompletion":1065,"completion":1065,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1802},"NCT00720759","Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine",[41],"2009-07",24,[20],[1787],{"trials":1804,"activeCount":8},[],{"trials":1806,"activeCount":8},[],{"trials":1808,"activeCount":8},[],{"intervention":1810,"totalTrials":211,"cells":1811},"calcifidiol",{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1813,"activeCount":8},[],{"trials":1815,"activeCount":8},[],{"trials":1817,"activeCount":8},[1818],{"nctId":1819,"briefTitle":1820,"status":63,"phases":1821,"completion":1822,"start":632,"conditions":1823,"interventions":1825},"NCT00018538","Calcifidol Therapy in Men With Cancer",[41],"2002-09",[1824],"Prostate Cancer",[1810],{"trials":1827,"activeCount":8},[],{"trials":1829,"activeCount":8},[],{"trials":1831,"activeCount":8},[],{"intervention":1833,"totalTrials":211,"cells":1834},"Botox",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1839,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1836,"activeCount":8},[],{"trials":1838,"activeCount":8},[],{"trials":1840,"activeCount":8},[1841],{"nctId":1842,"briefTitle":1843,"status":499,"phases":1844,"enrollment":8,"conditions":1845,"interventions":1847},"NCT00262496","Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.",[41],[1469,1846],"Urinary Incontinence",[1833],{"trials":1849,"activeCount":8},[],{"trials":1851,"activeCount":8},[],{"trials":1853,"activeCount":8},[],{"intervention":1855,"totalTrials":211,"cells":1856},"Chemotherapy",{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1869,"PHASE4":1871,"NA":1873},{"trials":1858,"activeCount":8},[],{"trials":1860,"activeCount":8},[],{"trials":1862,"activeCount":8},[1863],{"nctId":1864,"briefTitle":1865,"status":63,"phases":1866,"completion":105,"start":1645,"conditions":1867,"interventions":1868},"NCT00108290","Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer",[41],[1824],[1855],{"trials":1870,"activeCount":8},[],{"trials":1872,"activeCount":8},[],{"trials":1874,"activeCount":8},[],{"intervention":1876,"totalTrials":211,"cells":1877},"sodium phenylbutyrate",{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1879,"activeCount":8},[],{"trials":1881,"activeCount":8},[],{"trials":1883,"activeCount":8},[1884],{"nctId":1885,"briefTitle":1886,"status":63,"phases":1887,"primaryCompletion":1888,"completion":227,"start":731,"enrollment":878,"conditions":1889,"interventions":1891},"NCT00107770","Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis)",[40,41],"2006-11",[1890],"Amyotrophic Lateral Sclerosis",[1876],{"trials":1893,"activeCount":8},[],{"trials":1895,"activeCount":8},[],{"trials":1897,"activeCount":8},[],{"intervention":146,"totalTrials":211,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1901,"activeCount":8},[],{"trials":1903,"activeCount":8},[],{"trials":1905,"activeCount":8},[1906],{"nctId":140,"briefTitle":141,"status":63,"phases":1907,"completion":65,"start":66,"conditions":1908,"interventions":1909},[41],[144],[146,131,147,148],{"trials":1911,"activeCount":8},[],{"trials":1913,"activeCount":8},[],{"trials":1915,"activeCount":8},[],{"intervention":147,"totalTrials":211,"cells":1917},{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1922,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1919,"activeCount":8},[],{"trials":1921,"activeCount":8},[],{"trials":1923,"activeCount":8},[1924],{"nctId":140,"briefTitle":141,"status":63,"phases":1925,"completion":65,"start":66,"conditions":1926,"interventions":1927},[41],[144],[146,131,147,148],{"trials":1929,"activeCount":8},[],{"trials":1931,"activeCount":8},[],{"trials":1933,"activeCount":8},[],{"intervention":185,"totalTrials":211,"cells":1935},{"EARLY_PHASE1":1936,"PHASE1":1938,"PHASE2":1940,"PHASE3":1946,"PHASE4":1948,"NA":1950},{"trials":1937,"activeCount":8},[],{"trials":1939,"activeCount":8},[],{"trials":1941,"activeCount":8},[1942],{"nctId":175,"briefTitle":176,"status":63,"phases":1943,"primaryCompletion":178,"completion":179,"start":180,"enrollment":181,"conditions":1944,"interventions":1945},[41],[183,14],[185,166],{"trials":1947,"activeCount":8},[],{"trials":1949,"activeCount":8},[],{"trials":1951,"activeCount":8},[],{"intervention":1953,"totalTrials":211,"cells":1954},"ethosuximide",{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1956,"activeCount":8},[],{"trials":1958,"activeCount":8},[],{"trials":1960,"activeCount":8},[1961],{"nctId":1962,"briefTitle":1963,"status":323,"phases":1964,"primaryCompletion":1965,"completion":1965,"start":1966,"enrollment":1967,"conditions":1968,"interventions":1970},"NCT01122381","Comparison of a Drug and Placebo in the Prevention of Migraine Headaches",[40,41],"2014-04","2011-12",5,[1969],"Headache, Migraine",[1953],{"trials":1972,"activeCount":8},[],{"trials":1974,"activeCount":8},[],{"trials":1976,"activeCount":8},[],{"intervention":1978,"totalTrials":211,"cells":1979},"Benztropine",{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1981,"activeCount":8},[],{"trials":1983,"activeCount":8},[],{"trials":1985,"activeCount":8},[1986],{"nctId":1987,"briefTitle":1988,"status":63,"phases":1989,"primaryCompletion":196,"completion":1990,"start":1991,"enrollment":1992,"conditions":1993,"interventions":1996},"NCT00018200","Effect of Antidepressants on Back Pain",[41],"2004-03","1999-04",130,[1994,1995],"Back Pain","Sciatica",[1997,1998,1978],"Desipramine","Fluoxetine",{"trials":2000,"activeCount":8},[],{"trials":2002,"activeCount":8},[],{"trials":2004,"activeCount":8},[],{"intervention":2006,"totalTrials":211,"cells":2007},"Topotecan",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2027,"PHASE4":2029,"NA":2031},{"trials":2009,"activeCount":8},[],{"trials":2011,"activeCount":8},[],{"trials":2013,"activeCount":8},[2014],{"nctId":2015,"briefTitle":2016,"status":63,"phases":2017,"primaryCompletion":2018,"completion":84,"start":2019,"enrollment":2020,"conditions":2021,"interventions":2024},"NCT00100477","Use of Topotecan in Patients With Refractory Acute Leukemia",[41],"2001-01","1998-08",10,[2022,2023],"Non-Hodgkin's Lymphoma","Leukemia",[2006,2025,2026],"Mitozantrone","Etoposide",{"trials":2028,"activeCount":8},[],{"trials":2030,"activeCount":8},[],{"trials":2032,"activeCount":8},[],{"intervention":2025,"totalTrials":211,"cells":2034},{"EARLY_PHASE1":2035,"PHASE1":2037,"PHASE2":2039,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2036,"activeCount":8},[],{"trials":2038,"activeCount":8},[],{"trials":2040,"activeCount":8},[2041],{"nctId":2015,"briefTitle":2016,"status":63,"phases":2042,"primaryCompletion":2018,"completion":84,"start":2019,"enrollment":2020,"conditions":2043,"interventions":2044},[41],[2022,2023],[2006,2025,2026],{"trials":2046,"activeCount":8},[],{"trials":2048,"activeCount":8},[],{"trials":2050,"activeCount":8},[],{"intervention":2026,"totalTrials":211,"cells":2052},{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2054,"activeCount":8},[],{"trials":2056,"activeCount":8},[],{"trials":2058,"activeCount":8},[2059],{"nctId":2015,"briefTitle":2016,"status":63,"phases":2060,"primaryCompletion":2018,"completion":84,"start":2019,"enrollment":2020,"conditions":2061,"interventions":2062},[41],[2022,2023],[2006,2025,2026],{"trials":2064,"activeCount":8},[],{"trials":2066,"activeCount":8},[],{"trials":2068,"activeCount":8},[],{"intervention":2070,"totalTrials":211,"cells":2071},"Ginkgo biloba",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2073,"activeCount":8},[],{"trials":2075,"activeCount":8},[],{"trials":2077,"activeCount":8},[2078],{"nctId":2079,"briefTitle":2080,"status":63,"phases":2081,"primaryCompletion":2082,"completion":656,"start":2083,"enrollment":2084,"conditions":2085,"interventions":2088},"NCT00841321","Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis",[41],"2010-11","2009-01",120,[2086,2087],"Multiple Sclerosis","Cognitive Ability, General",[2070],{"trials":2090,"activeCount":8},[],{"trials":2092,"activeCount":8},[],{"trials":2094,"activeCount":8},[],{"intervention":2096,"totalTrials":211,"cells":2097},"estrogen",{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2110,"PHASE4":2112,"NA":2114},{"trials":2099,"activeCount":8},[],{"trials":2101,"activeCount":8},[],{"trials":2103,"activeCount":8},[2104],{"nctId":2105,"briefTitle":2106,"status":63,"phases":2107,"completion":1773,"start":1532,"conditions":2108,"interventions":2109},"NCT00018343","Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen",[41],[1605],[2096],{"trials":2111,"activeCount":8},[],{"trials":2113,"activeCount":8},[],{"trials":2115,"activeCount":8},[],{"intervention":2117,"totalTrials":211,"cells":2118},"PTH 1-34",{"EARLY_PHASE1":2119,"PHASE1":2121,"PHASE2":2123,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2120,"activeCount":8},[],{"trials":2122,"activeCount":8},[],{"trials":2124,"activeCount":8},[2125],{"nctId":2126,"briefTitle":2127,"status":63,"phases":2128,"completion":66,"start":1647,"conditions":2129,"interventions":2131},"NCT00018447","Combination Osteogenic Therapy in Established Osteoporosis",[41],[2130],"Osteoporosis, Post-Menopausal",[2117,2132],"MFPSR-fluoride",{"trials":2134,"activeCount":8},[],{"trials":2136,"activeCount":8},[],{"trials":2138,"activeCount":8},[],{"intervention":2132,"totalTrials":211,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2145,"PHASE3":2151,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":8},[],{"trials":2144,"activeCount":8},[],{"trials":2146,"activeCount":8},[2147],{"nctId":2126,"briefTitle":2127,"status":63,"phases":2148,"completion":66,"start":1647,"conditions":2149,"interventions":2150},[41],[2130],[2117,2132],{"trials":2152,"activeCount":8},[],{"trials":2154,"activeCount":8},[],{"trials":2156,"activeCount":8},[],{"intervention":2158,"totalTrials":211,"cells":2159},"Inert placebo",{"EARLY_PHASE1":2160,"PHASE1":2162,"PHASE2":2164,"PHASE3":2175,"PHASE4":2177,"NA":2179},{"trials":2161,"activeCount":8},[],{"trials":2163,"activeCount":8},[],{"trials":2165,"activeCount":8},[2166],{"nctId":2167,"briefTitle":2168,"status":63,"phases":2169,"primaryCompletion":1799,"completion":1490,"start":836,"enrollment":2170,"conditions":2171,"interventions":2173},"NCT00108550","Chronic Low Back Pain Research Project",[41],108,[2172],"Chronic Low Back Pain",[2174,2158],"gabapentin",{"trials":2176,"activeCount":8},[],{"trials":2178,"activeCount":8},[],{"trials":2180,"activeCount":8},[],{"intervention":2182,"totalTrials":211,"cells":2183},"DITPA",{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2198,"PHASE4":2200,"NA":2202},{"trials":2185,"activeCount":8},[],{"trials":2187,"activeCount":8},[],{"trials":2189,"activeCount":8},[2190],{"nctId":2191,"briefTitle":2192,"status":323,"phases":2193,"primaryCompletion":774,"completion":774,"start":2194,"enrollment":2195,"conditions":2196,"interventions":2197},"NCT00032643","A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)",[41],"2004-06",150,[232],[2182],{"trials":2199,"activeCount":8},[],{"trials":2201,"activeCount":8},[],{"trials":2203,"activeCount":8},[],{"intervention":2205,"totalTrials":211,"cells":2206},"Folic Acid",{"EARLY_PHASE1":2207,"PHASE1":2209,"PHASE2":2211,"PHASE3":2222,"PHASE4":2224,"NA":2226},{"trials":2208,"activeCount":8},[],{"trials":2210,"activeCount":8},[],{"trials":2212,"activeCount":8},[2213],{"nctId":2214,"briefTitle":2215,"status":63,"phases":2216,"completion":1577,"start":526,"conditions":2217,"interventions":2221},"NCT00018551","Chemoprevention With Folic Acid",[41],[2218,2219,2220],"Colon Cancer","Adenoma","Colonic Polyps",[2205],{"trials":2223,"activeCount":8},[],{"trials":2225,"activeCount":8},[],{"trials":2227,"activeCount":8},[],{"intervention":2229,"totalTrials":211,"cells":2230},"MAS-1 adjuvant and influenza HA antigen",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2232,"activeCount":8},[],{"trials":2234,"activeCount":8},[],{"trials":2236,"activeCount":8},[2237],{"nctId":2238,"briefTitle":2239,"status":499,"phases":2240,"primaryCompletion":2241,"completion":2242,"start":1601,"enrollment":8,"conditions":2243,"interventions":2246},"NCT01623232","MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly",[40,41],"2013-11","2014-06",[2244,2245],"Influenza Vaccines","Aged",[2229,2247],"standard dose, inactivated trivalent influenza vaccine",{"trials":2249,"activeCount":8},[],{"trials":2251,"activeCount":8},[],{"trials":2253,"activeCount":8},[],{"intervention":2247,"totalTrials":211,"cells":2255},{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2266,"PHASE4":2268,"NA":2270},{"trials":2257,"activeCount":8},[],{"trials":2259,"activeCount":8},[],{"trials":2261,"activeCount":8},[2262],{"nctId":2238,"briefTitle":2239,"status":499,"phases":2263,"primaryCompletion":2241,"completion":2242,"start":1601,"enrollment":8,"conditions":2264,"interventions":2265},[40,41],[2244,2245],[2229,2247],{"trials":2267,"activeCount":8},[],{"trials":2269,"activeCount":8},[],{"trials":2271,"activeCount":8},[],{"intervention":2273,"totalTrials":211,"cells":2274},"Donepezil, 5 mg daily",{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2276,"activeCount":8},[],{"trials":2278,"activeCount":8},[],{"trials":2280,"activeCount":8},[2281],{"nctId":2282,"briefTitle":2283,"status":63,"phases":2284,"primaryCompletion":2285,"completion":2285,"start":254,"enrollment":658,"conditions":2286,"interventions":2288},"NCT00467389","Use of Donepezil for Treatment of Cocaine Dependence",[41],"2008-09",[2287],"Cocaine Abuse and Dependence",[2273],{"trials":2290,"activeCount":8},[],{"trials":2292,"activeCount":8},[],{"trials":2294,"activeCount":8},[],{"intervention":2296,"totalTrials":211,"cells":2297},"nortriptyline",{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2314,"PHASE4":2316,"NA":2318},{"trials":2299,"activeCount":8},[],{"trials":2301,"activeCount":8},[],{"trials":2303,"activeCount":8},[2304],{"nctId":2305,"briefTitle":2306,"status":63,"phases":2307,"primaryCompletion":2308,"completion":2309,"start":1532,"enrollment":2310,"conditions":2311,"interventions":2312},"NCT00018148","Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation",[41],"2002-12","2003-01",158,[1693],[2296,2313],"transdermal nicotine",{"trials":2315,"activeCount":8},[],{"trials":2317,"activeCount":8},[],{"trials":2319,"activeCount":8},[],{"intervention":2321,"totalTrials":211,"cells":2322},"IN NEO",{"EARLY_PHASE1":2323,"PHASE1":2325,"PHASE2":2327,"PHASE3":2339,"PHASE4":2341,"NA":2343},{"trials":2324,"activeCount":8},[],{"trials":2326,"activeCount":8},[],{"trials":2328,"activeCount":8},[2329],{"nctId":2330,"briefTitle":2331,"status":63,"phases":2332,"primaryCompletion":178,"completion":178,"start":1600,"enrollment":2333,"conditions":2334,"interventions":2336},"NCT00855283","Intranasal Administration of a Prokinetic for Bowel Evacuation in Persons With SCI",[41],20,[2335],"SCI",[2321,2321,2321,2337,2338],"IN NEO + IN Glycopyrrolate","IV Visit",{"trials":2340,"activeCount":8},[],{"trials":2342,"activeCount":8},[],{"trials":2344,"activeCount":8},[],{"intervention":2337,"totalTrials":211,"cells":2346},{"EARLY_PHASE1":2347,"PHASE1":2349,"PHASE2":2351,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2348,"activeCount":8},[],{"trials":2350,"activeCount":8},[],{"trials":2352,"activeCount":8},[2353],{"nctId":2330,"briefTitle":2331,"status":63,"phases":2354,"primaryCompletion":178,"completion":178,"start":1600,"enrollment":2333,"conditions":2355,"interventions":2356},[41],[2335],[2321,2321,2321,2337,2338],{"trials":2358,"activeCount":8},[],{"trials":2360,"activeCount":8},[],{"trials":2362,"activeCount":8},[],{"intervention":2338,"totalTrials":211,"cells":2364},{"EARLY_PHASE1":2365,"PHASE1":2367,"PHASE2":2369,"PHASE3":2375,"PHASE4":2377,"NA":2379},{"trials":2366,"activeCount":8},[],{"trials":2368,"activeCount":8},[],{"trials":2370,"activeCount":8},[2371],{"nctId":2330,"briefTitle":2331,"status":63,"phases":2372,"primaryCompletion":178,"completion":178,"start":1600,"enrollment":2333,"conditions":2373,"interventions":2374},[41],[2335],[2321,2321,2321,2337,2338],{"trials":2376,"activeCount":8},[],{"trials":2378,"activeCount":8},[],{"trials":2380,"activeCount":8},[],{"intervention":2382,"totalTrials":211,"cells":2383},"pregnenolone",{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2388,"PHASE3":2399,"PHASE4":2401,"NA":2403},{"trials":2385,"activeCount":8},[],{"trials":2387,"activeCount":8},[],{"trials":2389,"activeCount":8},[2390],{"nctId":2391,"briefTitle":2392,"status":499,"phases":2393,"primaryCompletion":180,"completion":180,"start":2394,"enrollment":8,"conditions":2395,"interventions":2398},"NCT00993629","Adjunctive Pregnenolone in Post-Traumatic Stress Disorder (PTSD) and Depression in Operations Enduring Freedom and Iraqi Freedom (OEF\u002FOIF) Veterans",[41],"2010-01",[2396,2397],"Post-traumatic Stress Disorder","Major Depressive Disorder",[2382],{"trials":2400,"activeCount":8},[],{"trials":2402,"activeCount":8},[],{"trials":2404,"activeCount":8},[],{"intervention":1695,"totalTrials":211,"cells":2406},{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2415,"PHASE3":2417,"PHASE4":2419,"NA":2421},{"trials":2408,"activeCount":8},[],{"trials":2410,"activeCount":8},[2411],{"nctId":1689,"briefTitle":1690,"status":63,"phases":2412,"completion":84,"start":1647,"conditions":2413,"interventions":2414},[40],[1693],[1695,1682,1696],{"trials":2416,"activeCount":8},[],{"trials":2418,"activeCount":8},[],{"trials":2420,"activeCount":8},[],{"trials":2422,"activeCount":8},[],{"intervention":2424,"totalTrials":211,"cells":2425},"Tumor RNA transfected dendritic cells",{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2436,"PHASE3":2438,"PHASE4":2440,"NA":2442},{"trials":2427,"activeCount":8},[],{"trials":2429,"activeCount":8},[2430],{"nctId":2431,"briefTitle":2432,"status":63,"phases":2433,"completion":1425,"conditions":2434,"interventions":2435},"NCT00108264","Tumor RNA Transfected Dendritic Cell Vaccines",[40],[1824],[2424],{"trials":2437,"activeCount":8},[],{"trials":2439,"activeCount":8},[],{"trials":2441,"activeCount":8},[],{"trials":2443,"activeCount":8},[],{"intervention":2445,"totalTrials":211,"cells":2446},"Gemfibrozil",{"EARLY_PHASE1":2447,"PHASE1":2449,"PHASE2":2458,"PHASE3":2460,"PHASE4":2462,"NA":2464},{"trials":2448,"activeCount":8},[],{"trials":2450,"activeCount":8},[2451],{"nctId":2452,"briefTitle":2453,"status":63,"phases":2454,"completion":227,"start":836,"conditions":2455,"interventions":2457},"NCT00108511","Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides",[40],[2456],"Hypertriglyceridemia",[2445],{"trials":2459,"activeCount":8},[],{"trials":2461,"activeCount":8},[],{"trials":2463,"activeCount":8},[],{"trials":2465,"activeCount":8},[],{"intervention":2467,"totalTrials":211,"cells":2468},"Zyban",{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2481,"PHASE3":2483,"PHASE4":2485,"NA":2487},{"trials":2470,"activeCount":8},[],{"trials":2472,"activeCount":8},[2473],{"nctId":2474,"briefTitle":2475,"status":63,"phases":2476,"primaryCompletion":587,"completion":835,"start":368,"enrollment":2477,"conditions":2478,"interventions":2480},"NCT00108173","Brain Reaction to Treatment of Nicotine Dependence",[40],104,[2479],"Nicotine Dependence",[2467],{"trials":2482,"activeCount":8},[],{"trials":2484,"activeCount":8},[],{"trials":2486,"activeCount":8},[],{"trials":2488,"activeCount":8},[],{"intervention":2490,"totalTrials":211,"cells":2491},"Insertion of urinary catheters coated with E. coli 83972",{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2506,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2493,"activeCount":8},[],{"trials":2495,"activeCount":8},[2496],{"nctId":2497,"briefTitle":2498,"status":63,"phases":2499,"primaryCompletion":2500,"completion":2501,"start":2502,"enrollment":36,"conditions":2503,"interventions":2505},"NCT00371631","Colonizing Neurogenic Bladders With Benign Flora",[40],"2008-02","2008-04","2006-10",[14,2504],"Urinary Tract Infection",[2490],{"trials":2507,"activeCount":8},[],{"trials":2509,"activeCount":8},[],{"trials":2511,"activeCount":8},[],{"trials":2513,"activeCount":8},[],{"intervention":2515,"totalTrials":211,"cells":2516},"guanfacine",{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2518,"activeCount":8},[],{"trials":2520,"activeCount":8},[2521],{"nctId":2522,"briefTitle":2523,"status":63,"phases":2524,"completion":368,"start":2525,"conditions":2526,"interventions":2528},"NCT00018603","Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)",[40],"1999-11",[2527],"Post-Traumatic Stress Disorder",[2515],{"trials":2530,"activeCount":8},[],{"trials":2532,"activeCount":8},[],{"trials":2534,"activeCount":8},[],{"trials":2536,"activeCount":8},[],{"intervention":2538,"totalTrials":211,"cells":2539},"Bupropion Sustained Release",{"EARLY_PHASE1":2540,"PHASE1":2552,"PHASE2":2554,"PHASE3":2556,"PHASE4":2558,"NA":2560},{"trials":2541,"activeCount":8},[2542],{"nctId":2543,"briefTitle":2544,"status":63,"phases":2545,"primaryCompletion":683,"completion":683,"start":2546,"enrollment":2547,"conditions":2548,"interventions":2550},"NCT00625131","Nicotine Patch Pretreatment for Smoking Cessation in PTSD",[39],"2008-05",87,[2549,1427],"Stress Disorders, Posttraumatic",[2551,2538],"Nicotine",{"trials":2553,"activeCount":8},[],{"trials":2555,"activeCount":8},[],{"trials":2557,"activeCount":8},[],{"trials":2559,"activeCount":8},[],{"trials":2561,"activeCount":8},[],{"intervention":2563,"totalTrials":2564,"cells":2565},"paroxetine",6,{"EARLY_PHASE1":2566,"PHASE1":2568,"PHASE2":2570,"PHASE3":2572,"PHASE4":2574,"NA":2595},{"trials":2567,"activeCount":8},[],{"trials":2569,"activeCount":8},[],{"trials":2571,"activeCount":8},[],{"trials":2573,"activeCount":8},[],{"trials":2575,"activeCount":8},[2576,2582,2591],{"nctId":2577,"briefTitle":2578,"status":63,"phases":2579,"completion":66,"start":1773,"conditions":2580,"interventions":2581},"NCT00018759","Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients",[43],[17,29],[2563],{"nctId":2583,"briefTitle":2584,"status":63,"phases":2585,"primaryCompletion":2586,"completion":2586,"start":2587,"enrollment":2588,"conditions":2589,"interventions":2590},"NCT00700999","Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)",[43],"2012-03","2008-10",65,[2396],[820],{"nctId":814,"briefTitle":815,"status":63,"phases":2592,"primaryCompletion":196,"completion":196,"start":817,"conditions":2593,"interventions":2594},[43],[107],[820,801],{"trials":2596,"activeCount":8},[2597,2605,2613],{"nctId":2598,"briefTitle":2599,"status":499,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2285,"enrollment":8,"conditions":2602,"interventions":2604},"NCT00641173","Early Intervention for Post Traumatic Stress Disorder (PTSD)",[44],"2011-04",[2603],"Post-Traumatic Stress Disorders",[2563],{"nctId":2606,"briefTitle":2607,"status":63,"phases":2608,"completion":2609,"start":2610,"conditions":2611,"interventions":2612},"NCT00018733","Biological Aspects of Depression and Antidepressant Drugs",[44],"2001-12","1996-09",[17],[2563,1997],{"nctId":2614,"briefTitle":2615,"status":63,"phases":2616,"primaryCompletion":1602,"completion":2617,"start":2618,"enrollment":2619,"conditions":2620,"interventions":2621},"NCT00261729","Prazosin vs. Paroxetine in Combat Stress Symptoms in OIF\u002FOEF Returnees",[44],"2009-12","2004-07",210,[662,35],[820,2622],"Prazosin",{"intervention":70,"totalTrials":2624,"cells":2625},4,{"EARLY_PHASE1":2626,"PHASE1":2628,"PHASE2":2630,"PHASE3":2643,"PHASE4":2645,"NA":2655},{"trials":2627,"activeCount":8},[],{"trials":2629,"activeCount":8},[],{"trials":2631,"activeCount":8},[2632],{"nctId":2633,"briefTitle":2634,"status":63,"phases":2635,"primaryCompletion":2636,"completion":2637,"start":2502,"enrollment":2638,"conditions":2639,"interventions":2642},"NCT00099983","Risperidone Treatment for Military Service Related Chronic Post Traumatic Stress Disorder",[41],"2010-02","2011-01",296,[2640,2641],"Stress Disorders","Post-Traumatic",[70],{"trials":2644,"activeCount":8},[],{"trials":2646,"activeCount":8},[2647,2651],{"nctId":61,"briefTitle":62,"status":63,"phases":2648,"completion":65,"start":66,"conditions":2649,"interventions":2650},[43],[23,68],[70,47],{"nctId":72,"briefTitle":73,"status":63,"phases":2652,"completion":75,"start":76,"conditions":2653,"interventions":2654},[43],[23],[70,47,79],{"trials":2656,"activeCount":8},[2657],{"nctId":2658,"briefTitle":2659,"status":63,"phases":2660,"completion":631,"start":2018,"conditions":2661,"interventions":2662},"NCT00018291","Specific Interventions for Agitation in Alzheimer's Disease",[44],[1605,1776],[70,1323],{"intervention":2664,"totalTrials":48,"cells":2665},"rosiglitazone",{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2678,"PHASE4":2680,"NA":2682},{"trials":2667,"activeCount":8},[],{"trials":2669,"activeCount":8},[],{"trials":2671,"activeCount":8},[2672],{"nctId":2673,"briefTitle":2674,"status":63,"phases":2675,"completion":1317,"start":632,"conditions":2676,"interventions":2677},"NCT00018382","Insulin, Neurogenetics and Memory in Alzheimer's Disease",[41],[528],[2664],{"trials":2679,"activeCount":8},[],{"trials":2681,"activeCount":8},[],{"trials":2683,"activeCount":8},[2684,2694],{"nctId":2685,"briefTitle":2686,"status":63,"phases":2687,"primaryCompletion":2546,"completion":2546,"start":2688,"enrollment":2689,"conditions":2690,"interventions":2692},"NCT00256646","Markers and Mechanisms of Vascular Disease in Type II Diabetes",[],"2007-06",298,[2691],"Type 2 Diabetes Mellitus",[2693],"Rosiglitazone",{"nctId":2695,"briefTitle":2696,"status":323,"phases":2697,"primaryCompletion":194,"completion":194,"start":2698,"enrollment":36,"conditions":2699,"interventions":2702},"NCT00252499","Insulin Resistance in Non-alcoholic Fatty Liver Disease",[44],"2005-10",[2700,2701],"Fatty Liver","Insulin Resistance",[2664,2703],"fenofibrate",{"intervention":1998,"totalTrials":48,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2716,"PHASE4":2726,"NA":2728},{"trials":2707,"activeCount":8},[],{"trials":2709,"activeCount":8},[],{"trials":2711,"activeCount":8},[2712],{"nctId":1987,"briefTitle":1988,"status":63,"phases":2713,"primaryCompletion":196,"completion":1990,"start":1991,"enrollment":1992,"conditions":2714,"interventions":2715},[41],[1994,1995],[1997,1998,1978],{"trials":2717,"activeCount":8},[2718],{"nctId":2719,"briefTitle":2720,"status":63,"phases":2721,"primaryCompletion":2309,"completion":631,"start":2722,"enrollment":2723,"conditions":2724,"interventions":2725},"NCT00018174","Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers",[42],"1998-02",247,[17,1693],[1998],{"trials":2727,"activeCount":8},[],{"trials":2729,"activeCount":8},[2730],{"nctId":2731,"briefTitle":2732,"status":499,"phases":2733,"primaryCompletion":1425,"completion":1425,"start":589,"enrollment":8,"conditions":2734,"interventions":2735},"NCT00108316","Determinants in Antidepressant Outcomes",[44],[17],[1998],{"intervention":2622,"totalTrials":48,"cells":2737},{"EARLY_PHASE1":2738,"PHASE1":2740,"PHASE2":2742,"PHASE3":2744,"PHASE4":2746,"NA":2755},{"trials":2739,"activeCount":8},[],{"trials":2741,"activeCount":8},[],{"trials":2743,"activeCount":8},[],{"trials":2745,"activeCount":8},[],{"trials":2747,"activeCount":8},[2748],{"nctId":2749,"briefTitle":2750,"status":63,"phases":2751,"completion":105,"start":66,"conditions":2752,"interventions":2754},"NCT00108420","Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance",[43],[2753],"Stress Disorder, Post-Traumatic",[2622],{"trials":2756,"activeCount":8},[2757,2765],{"nctId":2758,"briefTitle":2759,"status":323,"phases":2760,"primaryCompletion":2083,"completion":2083,"start":1645,"enrollment":2761,"conditions":2762,"interventions":2764},"NCT00240227","Prazosin for ETOH or Cocaine Craving",[44],8,[635,2763],"Cocaine Dependence",[2622],{"nctId":2614,"briefTitle":2615,"status":63,"phases":2766,"primaryCompletion":1602,"completion":2617,"start":2618,"enrollment":2619,"conditions":2767,"interventions":2768},[44],[662,35],[820,2622],{"intervention":1323,"totalTrials":48,"cells":2770},{"EARLY_PHASE1":2771,"PHASE1":2773,"PHASE2":2775,"PHASE3":2781,"PHASE4":2787,"NA":2789},{"trials":2772,"activeCount":8},[],{"trials":2774,"activeCount":8},[],{"trials":2776,"activeCount":8},[2777],{"nctId":2167,"briefTitle":2168,"status":63,"phases":2778,"primaryCompletion":1799,"completion":1490,"start":836,"enrollment":2170,"conditions":2779,"interventions":2780},[41],[2172],[2174,2158],{"trials":2782,"activeCount":8},[2783],{"nctId":1314,"briefTitle":1315,"status":63,"phases":2784,"completion":1317,"start":1318,"enrollment":1319,"conditions":2785,"interventions":2786},[42],[1321],[1303,1323,1324],{"trials":2788,"activeCount":8},[],{"trials":2790,"activeCount":8},[2791],{"nctId":2658,"briefTitle":2659,"status":63,"phases":2792,"completion":631,"start":2018,"conditions":2793,"interventions":2794},[44],[1605,1776],[70,1323],{"intervention":2796,"totalTrials":95,"cells":2797},"N-acetylcysteine",{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2799,"activeCount":8},[],{"trials":2801,"activeCount":8},[],{"trials":2803,"activeCount":8},[],{"trials":2805,"activeCount":8},[],{"trials":2807,"activeCount":8},[],{"trials":2809,"activeCount":8},[2810,2818],{"nctId":2811,"briefTitle":2812,"status":63,"phases":2813,"primaryCompletion":588,"completion":588,"start":708,"enrollment":2814,"conditions":2815,"interventions":2817},"NCT00493727","Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria",[44],15,[26,2816],"Proteinuria",[2796],{"nctId":2819,"briefTitle":2820,"status":2821,"phases":2822,"primaryCompletion":2823,"completion":2823,"start":1888,"enrollment":1967,"conditions":2824,"interventions":2825},"NCT00493610","Mucomyst for Hepatitis C","SUSPENDED",[44],"2008-06",[710],[2796],{"intervention":79,"totalTrials":95,"cells":2827},{"EARLY_PHASE1":2828,"PHASE1":2830,"PHASE2":2832,"PHASE3":2834,"PHASE4":2836,"NA":2842},{"trials":2829,"activeCount":8},[],{"trials":2831,"activeCount":8},[],{"trials":2833,"activeCount":8},[],{"trials":2835,"activeCount":8},[],{"trials":2837,"activeCount":8},[2838],{"nctId":72,"briefTitle":73,"status":63,"phases":2839,"completion":75,"start":76,"conditions":2840,"interventions":2841},[43],[23],[70,47,79],{"trials":2843,"activeCount":8},[2844],{"nctId":2845,"briefTitle":2846,"status":63,"phases":2847,"completion":2848,"start":2849,"conditions":2850,"interventions":2851},"NCT00018642","Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder",[44],"2002-03","1997-04",[23,88],[2852,2853],"quetiapine","haloperidol decanoate",{"intervention":2855,"totalTrials":95,"cells":2856},"Transdermal Nicotine",{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2858,"activeCount":8},[],{"trials":2860,"activeCount":8},[],{"trials":2862,"activeCount":8},[2863],{"nctId":2305,"briefTitle":2306,"status":63,"phases":2864,"primaryCompletion":2308,"completion":2309,"start":1532,"enrollment":2310,"conditions":2865,"interventions":2866},[41],[1693],[2296,2313],{"trials":2868,"activeCount":8},[],{"trials":2870,"activeCount":8},[],{"trials":2872,"activeCount":8},[2873],{"nctId":2874,"briefTitle":2875,"status":63,"phases":2876,"completion":1773,"start":1532,"conditions":2877,"interventions":2878},"NCT00018213","Naltrexone and Patch for Smokers",[44],[1693],[2879,2855],"Naltrexone Hydrochloride",{"intervention":2881,"totalTrials":95,"cells":2882},"methylphenidate",{"EARLY_PHASE1":2883,"PHASE1":2885,"PHASE2":2887,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2884,"activeCount":8},[],{"trials":2886,"activeCount":8},[],{"trials":2888,"activeCount":8},[],{"trials":2890,"activeCount":8},[],{"trials":2892,"activeCount":8},[],{"trials":2894,"activeCount":8},[2895,2903],{"nctId":2896,"briefTitle":2897,"status":499,"phases":2898,"primaryCompletion":228,"completion":228,"start":65,"enrollment":8,"conditions":2899,"interventions":2901},"NCT00393562","Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease",[44],[2900],"Parkinson's Disease",[2902,2881],"modafinil",{"nctId":2904,"briefTitle":2905,"status":63,"phases":2906,"primaryCompletion":1490,"completion":656,"start":255,"enrollment":2907,"conditions":2908,"interventions":2912},"NCT00129467","Methylphenidate for Depressed Cancer Patients Receiving Palliative Care",[44],47,[17,2909,2910,2911],"Palliative Care","Cancer","Mental Disorder",[2913,2914],"Methylphenidate","Selective Serotonin Uptake Inhibitor",{"intervention":1997,"totalTrials":95,"cells":2916},{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2927,"PHASE4":2929,"NA":2931},{"trials":2918,"activeCount":8},[],{"trials":2920,"activeCount":8},[],{"trials":2922,"activeCount":8},[2923],{"nctId":1987,"briefTitle":1988,"status":63,"phases":2924,"primaryCompletion":196,"completion":1990,"start":1991,"enrollment":1992,"conditions":2925,"interventions":2926},[41],[1994,1995],[1997,1998,1978],{"trials":2928,"activeCount":8},[],{"trials":2930,"activeCount":8},[],{"trials":2932,"activeCount":8},[2933],{"nctId":2606,"briefTitle":2607,"status":63,"phases":2934,"completion":2609,"start":2610,"conditions":2935,"interventions":2936},[44],[17],[2563,1997],{"intervention":2551,"totalTrials":95,"cells":2938},{"EARLY_PHASE1":2939,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2940,"activeCount":8},[2941],{"nctId":2543,"briefTitle":2544,"status":63,"phases":2942,"primaryCompletion":683,"completion":683,"start":2546,"enrollment":2547,"conditions":2943,"interventions":2944},[39],[2549,1427],[2551,2538],{"trials":2946,"activeCount":8},[],{"trials":2948,"activeCount":8},[],{"trials":2950,"activeCount":8},[],{"trials":2952,"activeCount":8},[],{"trials":2954,"activeCount":8},[2955],{"nctId":2956,"briefTitle":2957,"status":63,"phases":2958,"completion":1672,"start":2959,"conditions":2960,"interventions":2961},"NCT00018850","5HT3 Antagonism and Auditory Gating in Schizophrenia",[44],"1998-06",[23],[2962,2963,2964],"ondansetron","nicotine","haloperidol",{"intervention":90,"totalTrials":95,"cells":2966},{"EARLY_PHASE1":2967,"PHASE1":2969,"PHASE2":2971,"PHASE3":2973,"PHASE4":2975,"NA":2981},{"trials":2968,"activeCount":8},[],{"trials":2970,"activeCount":8},[],{"trials":2972,"activeCount":8},[],{"trials":2974,"activeCount":8},[],{"trials":2976,"activeCount":8},[2977],{"nctId":81,"briefTitle":82,"status":63,"phases":2978,"primaryCompletion":84,"start":85,"enrollment":86,"conditions":2979,"interventions":2980},[43],[88,23],[90,47],{"trials":2982,"activeCount":8},[2983],{"nctId":2956,"briefTitle":2957,"status":63,"phases":2984,"completion":1672,"start":2959,"conditions":2985,"interventions":2986},[44],[23],[2962,2963,2964],{"intervention":2988,"totalTrials":95,"cells":2989},"Oxandrolone",{"EARLY_PHASE1":2990,"PHASE1":2992,"PHASE2":2994,"PHASE3":2996,"PHASE4":3008,"NA":3010},{"trials":2991,"activeCount":8},[],{"trials":2993,"activeCount":8},[],{"trials":2995,"activeCount":8},[],{"trials":2997,"activeCount":8},[2998],{"nctId":2999,"briefTitle":3000,"status":323,"phases":3001,"primaryCompletion":3002,"completion":3002,"start":3003,"enrollment":3004,"conditions":3005,"interventions":3007},"NCT00101361","Oxandrolone to Heal Pressure Ulcers",[42],"2008-12","2005-08",212,[3006],"Pressure Ulcer",[2988],{"trials":3009,"activeCount":8},[],{"trials":3011,"activeCount":8},[3012],{"nctId":3013,"briefTitle":3014,"status":63,"phases":3015,"completion":3016,"start":589,"enrollment":878,"conditions":3017,"interventions":3018},"NCT00223769","The Use of Anabolic Steroids to Improve Function After Spinal Cord Injury",[44],"2006-05",[14],[2988],{"intervention":3020,"totalTrials":211,"cells":3021},"Paraoxonase",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3023,"activeCount":8},[],{"trials":3025,"activeCount":8},[],{"trials":3027,"activeCount":8},[],{"trials":3029,"activeCount":8},[],{"trials":3031,"activeCount":8},[],{"trials":3033,"activeCount":8},[3034],{"nctId":3035,"briefTitle":3036,"status":63,"phases":3037,"completion":1577,"start":3038,"enrollment":3039,"conditions":3040,"interventions":3042},"NCT00011258","Paraoxonase and LDL Oxidation in Carotid Artery Disease",[],"1997-03",1000,[3041],"Carotid Stenosis",[3020],{"intervention":3044,"totalTrials":211,"cells":3045},"spironolactone",{"EARLY_PHASE1":3046,"PHASE1":3048,"PHASE2":3050,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3047,"activeCount":8},[],{"trials":3049,"activeCount":8},[],{"trials":3051,"activeCount":8},[],{"trials":3053,"activeCount":8},[],{"trials":3055,"activeCount":8},[],{"trials":3057,"activeCount":8},[3058],{"nctId":3059,"briefTitle":3060,"status":63,"phases":3061,"primaryCompletion":3062,"completion":1293,"start":2309,"enrollment":18,"conditions":3063,"interventions":3065},"NCT00498537","Spironolactone for Reducing Proteinuria in Diabetic Nephropathy",[44],"2005-12",[3064],"Diabetic Nephropathy",[3044],{"intervention":3067,"totalTrials":211,"cells":3068},"Etanercept",{"EARLY_PHASE1":3069,"PHASE1":3071,"PHASE2":3073,"PHASE3":3075,"PHASE4":3077,"NA":3079},{"trials":3070,"activeCount":8},[],{"trials":3072,"activeCount":8},[],{"trials":3074,"activeCount":8},[],{"trials":3076,"activeCount":8},[],{"trials":3078,"activeCount":8},[],{"trials":3080,"activeCount":8},[3081],{"nctId":3082,"briefTitle":3083,"status":63,"phases":3084,"primaryCompletion":1966,"completion":3085,"start":657,"enrollment":3086,"conditions":3087,"interventions":3089},"NCT00405275","Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy",[44],"2012-05",353,[3088],"Rheumatoid Arthritis",[3067,3090,3091,3092],"methotrexate","Sulfasalazine","Hydroxychloroquine",{"intervention":3090,"totalTrials":211,"cells":3094},{"EARLY_PHASE1":3095,"PHASE1":3097,"PHASE2":3099,"PHASE3":3101,"PHASE4":3103,"NA":3105},{"trials":3096,"activeCount":8},[],{"trials":3098,"activeCount":8},[],{"trials":3100,"activeCount":8},[],{"trials":3102,"activeCount":8},[],{"trials":3104,"activeCount":8},[],{"trials":3106,"activeCount":8},[3107],{"nctId":3082,"briefTitle":3083,"status":63,"phases":3108,"primaryCompletion":1966,"completion":3085,"start":657,"enrollment":3086,"conditions":3109,"interventions":3110},[44],[3088],[3067,3090,3091,3092],{"intervention":3091,"totalTrials":211,"cells":3112},{"EARLY_PHASE1":3113,"PHASE1":3115,"PHASE2":3117,"PHASE3":3119,"PHASE4":3121,"NA":3123},{"trials":3114,"activeCount":8},[],{"trials":3116,"activeCount":8},[],{"trials":3118,"activeCount":8},[],{"trials":3120,"activeCount":8},[],{"trials":3122,"activeCount":8},[],{"trials":3124,"activeCount":8},[3125],{"nctId":3082,"briefTitle":3083,"status":63,"phases":3126,"primaryCompletion":1966,"completion":3085,"start":657,"enrollment":3086,"conditions":3127,"interventions":3128},[44],[3088],[3067,3090,3091,3092],{"intervention":3092,"totalTrials":211,"cells":3130},{"EARLY_PHASE1":3131,"PHASE1":3133,"PHASE2":3135,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3132,"activeCount":8},[],{"trials":3134,"activeCount":8},[],{"trials":3136,"activeCount":8},[],{"trials":3138,"activeCount":8},[],{"trials":3140,"activeCount":8},[],{"trials":3142,"activeCount":8},[3143],{"nctId":3082,"briefTitle":3083,"status":63,"phases":3144,"primaryCompletion":1966,"completion":3085,"start":657,"enrollment":3086,"conditions":3145,"interventions":3146},[44],[3088],[3067,3090,3091,3092],{"intervention":3148,"totalTrials":211,"cells":3149},"Doxycycline HCI 10mg po for 2 weeks",{"EARLY_PHASE1":3150,"PHASE1":3152,"PHASE2":3154,"PHASE3":3156,"PHASE4":3158,"NA":3160},{"trials":3151,"activeCount":8},[],{"trials":3153,"activeCount":8},[],{"trials":3155,"activeCount":8},[],{"trials":3157,"activeCount":8},[],{"trials":3159,"activeCount":8},[],{"trials":3161,"activeCount":8},[3162],{"nctId":3163,"briefTitle":3164,"status":63,"phases":3165,"completion":1577,"enrollment":3166,"conditions":3167,"interventions":3170},"NCT00012688","Periodontal Care and Glycemic Control in Diabetes",[44],300,[32,3168,3169],"Poor Glycemic Control","Peridontal Disease",[3148],{"intervention":3172,"totalTrials":211,"cells":3173},"Chenodeoxycholic Acid",{"EARLY_PHASE1":3174,"PHASE1":3176,"PHASE2":3178,"PHASE3":3180,"PHASE4":3182,"NA":3184},{"trials":3175,"activeCount":8},[],{"trials":3177,"activeCount":8},[],{"trials":3179,"activeCount":8},[],{"trials":3181,"activeCount":8},[],{"trials":3183,"activeCount":8},[],{"trials":3185,"activeCount":8},[3186],{"nctId":3187,"briefTitle":3188,"status":499,"phases":3189,"primaryCompletion":2617,"completion":2617,"start":632,"enrollment":8,"conditions":3190,"interventions":3192},"NCT00018694","Cholestanol in Humans",[44],[3191],"Cerebrotendinous Xanthomatosis",[3172],{"intervention":3194,"totalTrials":211,"cells":3195},"Fleets Oral Sodium Phosphate Solution",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3202,"PHASE4":3204,"NA":3206},{"trials":3197,"activeCount":8},[],{"trials":3199,"activeCount":8},[],{"trials":3201,"activeCount":8},[],{"trials":3203,"activeCount":8},[],{"trials":3205,"activeCount":8},[],{"trials":3207,"activeCount":8},[3208],{"nctId":3209,"briefTitle":3210,"status":63,"phases":3211,"primaryCompletion":3002,"completion":3002,"start":1293,"enrollment":3212,"conditions":3213,"interventions":3214},"NCT00856440","Safety and Efficacy of Routine Colonoscopy Preparations",[],330,[14],[3194,3215,3216],"Colyte","Dual",{"intervention":3215,"totalTrials":211,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3225,"PHASE4":3227,"NA":3229},{"trials":3220,"activeCount":8},[],{"trials":3222,"activeCount":8},[],{"trials":3224,"activeCount":8},[],{"trials":3226,"activeCount":8},[],{"trials":3228,"activeCount":8},[],{"trials":3230,"activeCount":8},[3231],{"nctId":3209,"briefTitle":3210,"status":63,"phases":3232,"primaryCompletion":3002,"completion":3002,"start":1293,"enrollment":3212,"conditions":3233,"interventions":3234},[],[14],[3194,3215,3216],{"intervention":3216,"totalTrials":211,"cells":3236},{"EARLY_PHASE1":3237,"PHASE1":3239,"PHASE2":3241,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3238,"activeCount":8},[],{"trials":3240,"activeCount":8},[],{"trials":3242,"activeCount":8},[],{"trials":3244,"activeCount":8},[],{"trials":3246,"activeCount":8},[],{"trials":3248,"activeCount":8},[3249],{"nctId":3209,"briefTitle":3210,"status":63,"phases":3250,"primaryCompletion":3002,"completion":3002,"start":1293,"enrollment":3212,"conditions":3251,"interventions":3252},[],[14],[3194,3215,3216],{"intervention":3254,"totalTrials":211,"cells":3255},"ipratropium",{"EARLY_PHASE1":3256,"PHASE1":3258,"PHASE2":3260,"PHASE3":3262,"PHASE4":3264,"NA":3266},{"trials":3257,"activeCount":8},[],{"trials":3259,"activeCount":8},[],{"trials":3261,"activeCount":8},[],{"trials":3263,"activeCount":8},[],{"trials":3265,"activeCount":8},[],{"trials":3267,"activeCount":8},[3268],{"nctId":3269,"briefTitle":3270,"status":63,"phases":3271,"primaryCompletion":2018,"completion":2018,"start":3272,"enrollment":2333,"conditions":3273,"interventions":3275},"NCT00904436","Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia",[44],"1999-12",[3274,661],"Dyspnea",[3254],{"intervention":3277,"totalTrials":211,"cells":3278},"Disease management of gastroesophageal reflux disease",{"EARLY_PHASE1":3279,"PHASE1":3281,"PHASE2":3283,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3280,"activeCount":8},[],{"trials":3282,"activeCount":8},[],{"trials":3284,"activeCount":8},[],{"trials":3286,"activeCount":8},[],{"trials":3288,"activeCount":8},[],{"trials":3290,"activeCount":8},[3291],{"nctId":3292,"briefTitle":3293,"status":63,"phases":3294,"completion":2194,"enrollment":3295,"conditions":3296,"interventions":3298},"NCT00057174","Economic Impact of Guidelines for Gastroesophageal Reflux Disease",[44],484,[1068,3297],"Health Economics",[3277],{"intervention":2703,"totalTrials":211,"cells":3300},{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3302,"activeCount":8},[],{"trials":3304,"activeCount":8},[],{"trials":3306,"activeCount":8},[],{"trials":3308,"activeCount":8},[],{"trials":3310,"activeCount":8},[],{"trials":3312,"activeCount":8},[3313],{"nctId":2695,"briefTitle":2696,"status":323,"phases":3314,"primaryCompletion":194,"completion":194,"start":2698,"enrollment":36,"conditions":3315,"interventions":3316},[44],[2700,2701],[2664,2703],{"intervention":3318,"totalTrials":211,"cells":3319},"Graded dobutamine infusions",{"EARLY_PHASE1":3320,"PHASE1":3322,"PHASE2":3324,"PHASE3":3326,"PHASE4":3328,"NA":3330},{"trials":3321,"activeCount":8},[],{"trials":3323,"activeCount":8},[],{"trials":3325,"activeCount":8},[],{"trials":3327,"activeCount":8},[],{"trials":3329,"activeCount":8},[],{"trials":3331,"activeCount":8},[3332],{"nctId":3333,"briefTitle":3334,"status":63,"phases":3335,"completion":1822,"start":632,"conditions":3336,"interventions":3339},"NCT00100412","Hyporeactivity and Gulf War Illness",[44],[3337,3338,2527],"Gulf War Syndrome","Chronic Fatigue Syndrome",[3318,3340],"Graded phenylephrine injections",{"intervention":3340,"totalTrials":211,"cells":3342},{"EARLY_PHASE1":3343,"PHASE1":3345,"PHASE2":3347,"PHASE3":3349,"PHASE4":3351,"NA":3353},{"trials":3344,"activeCount":8},[],{"trials":3346,"activeCount":8},[],{"trials":3348,"activeCount":8},[],{"trials":3350,"activeCount":8},[],{"trials":3352,"activeCount":8},[],{"trials":3354,"activeCount":8},[3355],{"nctId":3333,"briefTitle":3334,"status":63,"phases":3356,"completion":1822,"start":632,"conditions":3357,"interventions":3358},[44],[3337,3338,2527],[3318,3340],{"intervention":3360,"totalTrials":211,"cells":3361},"genetic testing for type 2 diabetes",{"EARLY_PHASE1":3362,"PHASE1":3364,"PHASE2":3366,"PHASE3":3368,"PHASE4":3370,"NA":3372},{"trials":3363,"activeCount":8},[],{"trials":3365,"activeCount":8},[],{"trials":3367,"activeCount":8},[],{"trials":3369,"activeCount":8},[],{"trials":3371,"activeCount":8},[],{"trials":3373,"activeCount":8},[3374],{"nctId":3375,"briefTitle":3376,"status":63,"phases":3377,"primaryCompletion":683,"completion":683,"start":194,"enrollment":3378,"conditions":3379,"interventions":3380},"NCT01060540","Genetic Testing for Type 2 Diabetes",[44],601,[32],[3360],{"intervention":3382,"totalTrials":211,"cells":3383},"Nicotine gum - 2 mg and 4 mg",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3388,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3385,"activeCount":8},[],{"trials":3387,"activeCount":8},[],{"trials":3389,"activeCount":8},[],{"trials":3391,"activeCount":8},[],{"trials":3393,"activeCount":8},[],{"trials":3395,"activeCount":8},[3396],{"nctId":3397,"briefTitle":3398,"status":323,"phases":3399,"primaryCompletion":1490,"completion":2617,"start":228,"enrollment":3400,"conditions":3401,"interventions":3402},"NCT00108342","Nicotine Delivery Systems: Research & Treatment",[44],25,[1693],[3382,3403,3404],"Nicotine lozenges - 2 mg and 4 mg","Nicotine inhaler (4 mg yield) - low and high \"dosage\" by frequency of puffing",{"intervention":3403,"totalTrials":211,"cells":3406},{"EARLY_PHASE1":3407,"PHASE1":3409,"PHASE2":3411,"PHASE3":3413,"PHASE4":3415,"NA":3417},{"trials":3408,"activeCount":8},[],{"trials":3410,"activeCount":8},[],{"trials":3412,"activeCount":8},[],{"trials":3414,"activeCount":8},[],{"trials":3416,"activeCount":8},[],{"trials":3418,"activeCount":8},[3419],{"nctId":3397,"briefTitle":3398,"status":323,"phases":3420,"primaryCompletion":1490,"completion":2617,"start":228,"enrollment":3400,"conditions":3421,"interventions":3422},[44],[1693],[3382,3403,3404],{"intervention":3404,"totalTrials":211,"cells":3424},{"EARLY_PHASE1":3425,"PHASE1":3427,"PHASE2":3429,"PHASE3":3431,"PHASE4":3433,"NA":3435},{"trials":3426,"activeCount":8},[],{"trials":3428,"activeCount":8},[],{"trials":3430,"activeCount":8},[],{"trials":3432,"activeCount":8},[],{"trials":3434,"activeCount":8},[],{"trials":3436,"activeCount":8},[3437],{"nctId":3397,"briefTitle":3398,"status":323,"phases":3438,"primaryCompletion":1490,"completion":2617,"start":228,"enrollment":3400,"conditions":3439,"interventions":3440},[44],[1693],[3382,3403,3404],{"intervention":3442,"totalTrials":211,"cells":3443},"prazosin hydrochloride",{"EARLY_PHASE1":3444,"PHASE1":3446,"PHASE2":3448,"PHASE3":3450,"PHASE4":3452,"NA":3454},{"trials":3445,"activeCount":8},[],{"trials":3447,"activeCount":8},[],{"trials":3449,"activeCount":8},[],{"trials":3451,"activeCount":8},[],{"trials":3453,"activeCount":8},[],{"trials":3455,"activeCount":8},[3456],{"nctId":3457,"briefTitle":3458,"status":499,"phases":3459,"primaryCompletion":835,"completion":3460,"start":2617,"enrollment":8,"conditions":3461,"interventions":3463},"NCT00890643","Effect of Prazosin on Neurophysiology and Cognition in Post-Traumatic Stress Disorder (PTSD)",[44],"2011-09",[3462],"Posttraumatic Stress Disorder",[3442],{"intervention":2879,"totalTrials":211,"cells":3465},{"EARLY_PHASE1":3466,"PHASE1":3468,"PHASE2":3470,"PHASE3":3472,"PHASE4":3474,"NA":3476},{"trials":3467,"activeCount":8},[],{"trials":3469,"activeCount":8},[],{"trials":3471,"activeCount":8},[],{"trials":3473,"activeCount":8},[],{"trials":3475,"activeCount":8},[],{"trials":3477,"activeCount":8},[3478],{"nctId":2874,"briefTitle":2875,"status":63,"phases":3479,"completion":1773,"start":1532,"conditions":3480,"interventions":3481},[44],[1693],[2879,2855],{"intervention":2902,"totalTrials":211,"cells":3483},{"EARLY_PHASE1":3484,"PHASE1":3486,"PHASE2":3488,"PHASE3":3490,"PHASE4":3492,"NA":3494},{"trials":3485,"activeCount":8},[],{"trials":3487,"activeCount":8},[],{"trials":3489,"activeCount":8},[],{"trials":3491,"activeCount":8},[],{"trials":3493,"activeCount":8},[],{"trials":3495,"activeCount":8},[3496],{"nctId":2896,"briefTitle":2897,"status":499,"phases":3497,"primaryCompletion":228,"completion":228,"start":65,"enrollment":8,"conditions":3498,"interventions":3499},[44],[2900],[2902,2881],{"intervention":3501,"totalTrials":211,"cells":3502},"methylphenidate or placebo",{"EARLY_PHASE1":3503,"PHASE1":3505,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3504,"activeCount":8},[],{"trials":3506,"activeCount":8},[],{"trials":3508,"activeCount":8},[],{"trials":3510,"activeCount":8},[],{"trials":3512,"activeCount":8},[],{"trials":3514,"activeCount":8},[3515],{"nctId":3516,"briefTitle":3517,"status":63,"phases":3518,"primaryCompletion":195,"completion":1601,"start":1799,"enrollment":3519,"conditions":3520,"interventions":3522},"NCT00844090","The Role of Apathy in Glycemic Control",[44],106,[3521,26],"Apathy",[3501],{"intervention":3524,"totalTrials":211,"cells":3525},"Simvastin",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3532,"PHASE4":3534,"NA":3536},{"trials":3527,"activeCount":8},[],{"trials":3529,"activeCount":8},[],{"trials":3531,"activeCount":8},[],{"trials":3533,"activeCount":8},[],{"trials":3535,"activeCount":8},[],{"trials":3537,"activeCount":8},[3538],{"nctId":3539,"briefTitle":3540,"status":63,"phases":3541,"completion":588,"start":1293,"enrollment":3542,"conditions":3543,"interventions":3545},"NCT00133094","Systematic Management of High Cholesterol Utilizing Computer Monitoring",[44],220,[3544],"Hypercholesterolemia",[3524],{"intervention":3547,"totalTrials":211,"cells":3548},"Levodopa",{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3555,"PHASE4":3557,"NA":3559},{"trials":3550,"activeCount":8},[],{"trials":3552,"activeCount":8},[],{"trials":3554,"activeCount":8},[],{"trials":3556,"activeCount":8},[],{"trials":3558,"activeCount":8},[],{"trials":3560,"activeCount":8},[3561],{"nctId":3562,"briefTitle":3563,"status":63,"phases":3564,"primaryCompletion":3565,"completion":944,"start":122,"enrollment":3566,"conditions":3567,"interventions":3571},"NCT00467597","Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1)",[],"2008-08",36,[3568,3569,3570],"Dyskinesias","Movement Disorders","Parkinson Disease",[3547],{"intervention":3573,"totalTrials":211,"cells":3574},"Nicotine Replacement therapy",{"EARLY_PHASE1":3575,"PHASE1":3577,"PHASE2":3579,"PHASE3":3581,"PHASE4":3583,"NA":3585},{"trials":3576,"activeCount":8},[],{"trials":3578,"activeCount":8},[],{"trials":3580,"activeCount":8},[],{"trials":3582,"activeCount":8},[],{"trials":3584,"activeCount":8},[],{"trials":3586,"activeCount":8},[3587],{"nctId":3588,"briefTitle":3589,"status":63,"phases":3590,"completion":65,"start":1317,"enrollment":3591,"conditions":3592,"interventions":3597},"NCT00075972","Mood and Smoking: A Comparison of Smoking Cessation Treatments",[44],128,[3593,3594,3595,3596],"Smoking Cessation","Mood Tolerance","Mood Management","Nicotine Replacement Therapy",[3573],{"intervention":3599,"totalTrials":211,"cells":3600},"(PV) 23-valent pneumococcal polysaccharide vaccine",{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3605,"PHASE3":3607,"PHASE4":3609,"NA":3611},{"trials":3602,"activeCount":8},[],{"trials":3604,"activeCount":8},[],{"trials":3606,"activeCount":8},[],{"trials":3608,"activeCount":8},[],{"trials":3610,"activeCount":8},[],{"trials":3612,"activeCount":8},[3613],{"nctId":3614,"briefTitle":3615,"status":63,"phases":3616,"primaryCompletion":3460,"completion":1600,"start":2587,"enrollment":3617,"conditions":3618,"interventions":3620},"NCT00706550","Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects",[44],107,[3619],"HIV Infections",[3599],{"intervention":3622,"totalTrials":211,"cells":3623},"Vitamin B",{"EARLY_PHASE1":3624,"PHASE1":3626,"PHASE2":3628,"PHASE3":3630,"PHASE4":3632,"NA":3634},{"trials":3625,"activeCount":8},[],{"trials":3627,"activeCount":8},[],{"trials":3629,"activeCount":8},[],{"trials":3631,"activeCount":8},[],{"trials":3633,"activeCount":8},[],{"trials":3635,"activeCount":8},[3636],{"nctId":3637,"briefTitle":3638,"status":63,"phases":3639,"completion":2848,"start":1991,"conditions":3640,"interventions":3642},"NCT00018460","Anticoagulation, Vitamins, and Endothelial Function",[44],[3641],"Cardiovascular Diseases",[3622],{"intervention":3644,"totalTrials":211,"cells":3645},"5% dextrose",{"EARLY_PHASE1":3646,"PHASE1":3648,"PHASE2":3650,"PHASE3":3652,"PHASE4":3654,"NA":3656},{"trials":3647,"activeCount":8},[],{"trials":3649,"activeCount":8},[],{"trials":3651,"activeCount":8},[],{"trials":3653,"activeCount":8},[],{"trials":3655,"activeCount":8},[],{"trials":3657,"activeCount":8},[3658],{"nctId":3659,"briefTitle":3660,"status":63,"phases":3661,"primaryCompletion":3662,"completion":3662,"start":3663,"enrollment":3664,"conditions":3665,"interventions":3667},"NCT00995670","Ischemia\u002FReperfusion Injury of Human Endothelium: Role of Glucose and Statins",[44],"2013-09","2010-03",59,[3666],"Hyperglycemia",[3644,3668,3669,3670],"Vitamin C","Simvastatin","Sevoflurane",{"intervention":3668,"totalTrials":211,"cells":3672},{"EARLY_PHASE1":3673,"PHASE1":3675,"PHASE2":3677,"PHASE3":3679,"PHASE4":3681,"NA":3683},{"trials":3674,"activeCount":8},[],{"trials":3676,"activeCount":8},[],{"trials":3678,"activeCount":8},[],{"trials":3680,"activeCount":8},[],{"trials":3682,"activeCount":8},[],{"trials":3684,"activeCount":8},[3685],{"nctId":3659,"briefTitle":3660,"status":63,"phases":3686,"primaryCompletion":3662,"completion":3662,"start":3663,"enrollment":3664,"conditions":3687,"interventions":3688},[44],[3666],[3644,3668,3669,3670],{"intervention":3669,"totalTrials":211,"cells":3690},{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3697,"PHASE4":3699,"NA":3701},{"trials":3692,"activeCount":8},[],{"trials":3694,"activeCount":8},[],{"trials":3696,"activeCount":8},[],{"trials":3698,"activeCount":8},[],{"trials":3700,"activeCount":8},[],{"trials":3702,"activeCount":8},[3703],{"nctId":3659,"briefTitle":3660,"status":63,"phases":3704,"primaryCompletion":3662,"completion":3662,"start":3663,"enrollment":3664,"conditions":3705,"interventions":3706},[44],[3666],[3644,3668,3669,3670],{"intervention":3670,"totalTrials":211,"cells":3708},{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3715,"PHASE4":3717,"NA":3719},{"trials":3710,"activeCount":8},[],{"trials":3712,"activeCount":8},[],{"trials":3714,"activeCount":8},[],{"trials":3716,"activeCount":8},[],{"trials":3718,"activeCount":8},[],{"trials":3720,"activeCount":8},[3721],{"nctId":3659,"briefTitle":3660,"status":63,"phases":3722,"primaryCompletion":3662,"completion":3662,"start":3663,"enrollment":3664,"conditions":3723,"interventions":3724},[44],[3666],[3644,3668,3669,3670],{"intervention":3726,"totalTrials":211,"cells":3727},"Oxybutynin chloride, extended-release, individually-titrated",{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3732,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3729,"activeCount":8},[],{"trials":3731,"activeCount":8},[],{"trials":3733,"activeCount":8},[],{"trials":3735,"activeCount":8},[],{"trials":3737,"activeCount":8},[],{"trials":3739,"activeCount":8},[3740],{"nctId":3741,"briefTitle":3742,"status":63,"phases":3743,"primaryCompletion":3744,"completion":2617,"start":1577,"enrollment":3745,"conditions":3746,"interventions":3747},"NCT00223821","Enhancing Conservative Treatment for Urge Incontinence",[44],"2008-11",166,[1846],[3726],{"intervention":3749,"totalTrials":211,"cells":3750},"Oxybutynin and darifenacin",{"EARLY_PHASE1":3751,"PHASE1":3753,"PHASE2":3755,"PHASE3":3757,"PHASE4":3759,"NA":3761},{"trials":3752,"activeCount":8},[],{"trials":3754,"activeCount":8},[],{"trials":3756,"activeCount":8},[],{"trials":3758,"activeCount":8},[],{"trials":3760,"activeCount":8},[],{"trials":3762,"activeCount":8},[3763],{"nctId":3764,"briefTitle":3765,"status":63,"phases":3766,"primaryCompletion":1203,"completion":1203,"start":3767,"enrollment":658,"conditions":3768,"interventions":3769},"NCT00892450","Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease",[44],"2009-05",[2900,1469],[3749],{"intervention":3771,"totalTrials":211,"cells":3772},"Ursodeoxycholic Acid",{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3774,"activeCount":8},[],{"trials":3776,"activeCount":8},[],{"trials":3778,"activeCount":8},[],{"trials":3780,"activeCount":8},[],{"trials":3782,"activeCount":8},[],{"trials":3784,"activeCount":8},[3785],{"nctId":3786,"briefTitle":3787,"status":63,"phases":3788,"primaryCompletion":683,"completion":3789,"start":685,"enrollment":3790,"conditions":3791,"interventions":3792},"NCT00858858","Clinical Studies on Bile Acids in Barrett's Esophagus",[44],"2015-02",60,[1068],[3771],{"intervention":3794,"totalTrials":211,"cells":3795},"D-Cycloserine",{"EARLY_PHASE1":3796,"PHASE1":3798,"PHASE2":3800,"PHASE3":3802,"PHASE4":3804,"NA":3806},{"trials":3797,"activeCount":8},[],{"trials":3799,"activeCount":8},[],{"trials":3801,"activeCount":8},[],{"trials":3803,"activeCount":8},[],{"trials":3805,"activeCount":8},[],{"trials":3807,"activeCount":8},[3808],{"nctId":3809,"briefTitle":3810,"status":63,"phases":3811,"primaryCompletion":3460,"completion":3812,"start":2502,"enrollment":24,"conditions":3813,"interventions":3815},"NCT00371176","A Placebo-Controlled Trial of D-Cycloserine and Exposure Therapy for Combat-PTSD",[44],"2012-07",[3814,35],"Combat Disorders",[3794],{"intervention":3817,"totalTrials":211,"cells":3818},"Rifaximin",{"EARLY_PHASE1":3819,"PHASE1":3821,"PHASE2":3823,"PHASE3":3825,"PHASE4":3827,"NA":3829},{"trials":3820,"activeCount":8},[],{"trials":3822,"activeCount":8},[],{"trials":3824,"activeCount":8},[],{"trials":3826,"activeCount":8},[],{"trials":3828,"activeCount":8},[],{"trials":3830,"activeCount":8},[3831],{"nctId":3832,"briefTitle":3833,"status":63,"phases":3834,"primaryCompletion":2587,"completion":945,"start":228,"enrollment":3835,"conditions":3836,"interventions":3838},"NCT00680836","Gulf War Digestive Health Study",[44],54,[144,3837],"Small Intestinal Bacterial Overgrowth",[3817],{"intervention":3840,"totalTrials":211,"cells":3841},"acetazolamide",{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3848,"PHASE4":3850,"NA":3852},{"trials":3843,"activeCount":8},[],{"trials":3845,"activeCount":8},[],{"trials":3847,"activeCount":8},[],{"trials":3849,"activeCount":8},[],{"trials":3851,"activeCount":8},[],{"trials":3853,"activeCount":8},[3854],{"nctId":3855,"briefTitle":3856,"status":499,"phases":3857,"primaryCompletion":3858,"completion":3858,"start":3858,"enrollment":8,"conditions":3859,"interventions":3861},"NCT00108602","Sleep Apnea: Mechanism and Cerebrovascular Consequences",[44],"2007-05",[3860,20],"Sleep Apnea, Obstructive",[3840],{"intervention":3863,"totalTrials":211,"cells":3864},"Orlistat",{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3866,"activeCount":8},[],{"trials":3868,"activeCount":8},[],{"trials":3870,"activeCount":8},[],{"trials":3872,"activeCount":8},[],{"trials":3874,"activeCount":8},[],{"trials":3876,"activeCount":8},[3877],{"nctId":3878,"briefTitle":3879,"status":63,"phases":3880,"primaryCompletion":588,"completion":588,"start":2618,"enrollment":732,"conditions":3881,"interventions":3883},"NCT00108524","A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss",[44],[32,3882],"Obesity",[3863],{"intervention":3885,"totalTrials":211,"cells":3886},"Chlorthalidone",{"EARLY_PHASE1":3887,"PHASE1":3889,"PHASE2":3891,"PHASE3":3893,"PHASE4":3895,"NA":3897},{"trials":3888,"activeCount":8},[],{"trials":3890,"activeCount":8},[],{"trials":3892,"activeCount":8},[],{"trials":3894,"activeCount":8},[],{"trials":3896,"activeCount":8},[],{"trials":3898,"activeCount":8},[3899],{"nctId":3900,"briefTitle":3901,"status":63,"phases":3902,"start":3903,"conditions":3904,"interventions":3905},"NCT00007592","Hypertension Screening and Treatment Program",[],"1989-06",[29],[3885,3906],"Furosemide",{"intervention":3906,"totalTrials":211,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3915,"PHASE4":3917,"NA":3919},{"trials":3910,"activeCount":8},[],{"trials":3912,"activeCount":8},[],{"trials":3914,"activeCount":8},[],{"trials":3916,"activeCount":8},[],{"trials":3918,"activeCount":8},[],{"trials":3920,"activeCount":8},[3921],{"nctId":3900,"briefTitle":3901,"status":63,"phases":3922,"start":3903,"conditions":3923,"interventions":3924},[],[29],[3885,3906],{"intervention":3926,"totalTrials":211,"cells":3927},"Baclofen",{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3932,"PHASE3":3934,"PHASE4":3936,"NA":3938},{"trials":3929,"activeCount":8},[],{"trials":3931,"activeCount":8},[],{"trials":3933,"activeCount":8},[],{"trials":3935,"activeCount":8},[],{"trials":3937,"activeCount":8},[],{"trials":3939,"activeCount":8},[3940],{"nctId":3941,"briefTitle":3942,"status":63,"phases":3943,"primaryCompletion":588,"completion":1966,"start":775,"enrollment":2333,"conditions":3944,"interventions":3945},"NCT00871455","Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study",[44],[14],[3926],{"intervention":3947,"totalTrials":211,"cells":3948},"Standard ART vs Mega ART",{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3953,"PHASE3":3955,"PHASE4":3957,"NA":3959},{"trials":3950,"activeCount":8},[],{"trials":3952,"activeCount":8},[],{"trials":3954,"activeCount":8},[],{"trials":3956,"activeCount":8},[],{"trials":3958,"activeCount":8},[],{"trials":3960,"activeCount":8},[3961],{"nctId":3962,"briefTitle":3963,"status":63,"phases":3964,"primaryCompletion":588,"completion":588,"start":2018,"enrollment":3965,"conditions":3966,"interventions":3968},"NCT00050089","CSP #512 - Options in Management With Anti-Retrovirals",[44],368,[3967,3619],"AIDS",[3947,3947,3947,3947],{"intervention":3970,"totalTrials":211,"cells":3971},"Human chorionic gonadotropin",{"EARLY_PHASE1":3972,"PHASE1":3974,"PHASE2":3976,"PHASE3":3978,"PHASE4":3980,"NA":3982},{"trials":3973,"activeCount":8},[],{"trials":3975,"activeCount":8},[],{"trials":3977,"activeCount":8},[],{"trials":3979,"activeCount":8},[],{"trials":3981,"activeCount":8},[],{"trials":3983,"activeCount":8},[3984],{"nctId":3985,"briefTitle":3986,"status":63,"phases":3987,"primaryCompletion":588,"completion":588,"start":3988,"enrollment":3989,"conditions":3990,"interventions":3992},"NCT00223860","Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.",[44],"2001-07",100,[3991,14],"Hypogonadism",[3970,3993],"Luteinizing hormone releasing hormone",{"intervention":3993,"totalTrials":211,"cells":3995},{"EARLY_PHASE1":3996,"PHASE1":3998,"PHASE2":4000,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3997,"activeCount":8},[],{"trials":3999,"activeCount":8},[],{"trials":4001,"activeCount":8},[],{"trials":4003,"activeCount":8},[],{"trials":4005,"activeCount":8},[],{"trials":4007,"activeCount":8},[4008],{"nctId":3985,"briefTitle":3986,"status":63,"phases":4009,"primaryCompletion":588,"completion":588,"start":3988,"enrollment":3989,"conditions":4010,"interventions":4011},[44],[3991,14],[3970,3993],{"intervention":4013,"totalTrials":211,"cells":4014},"20% Intralipid",{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4021,"PHASE4":4023,"NA":4025},{"trials":4016,"activeCount":8},[],{"trials":4018,"activeCount":8},[],{"trials":4020,"activeCount":8},[],{"trials":4022,"activeCount":8},[],{"trials":4024,"activeCount":8},[],{"trials":4026,"activeCount":8},[4027],{"nctId":4028,"briefTitle":4029,"status":63,"phases":4030,"primaryCompletion":4031,"completion":4032,"start":122,"enrollment":3400,"conditions":4033,"interventions":4035},"NCT00330967","Mechanisms of Insulin Resistance in Humans",[],"2012-01","2014-08",[4034,2701],"Inflammation",[4013],{"intervention":2853,"totalTrials":211,"cells":4037},{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4044,"PHASE4":4046,"NA":4048},{"trials":4039,"activeCount":8},[],{"trials":4041,"activeCount":8},[],{"trials":4043,"activeCount":8},[],{"trials":4045,"activeCount":8},[],{"trials":4047,"activeCount":8},[],{"trials":4049,"activeCount":8},[4050],{"nctId":2845,"briefTitle":2846,"status":63,"phases":4051,"completion":2848,"start":2849,"conditions":4052,"interventions":4053},[44],[23,88],[2852,2853],{"intervention":4055,"totalTrials":211,"cells":4056},"50K vitamin D2",{"EARLY_PHASE1":4057,"PHASE1":4059,"PHASE2":4061,"PHASE3":4063,"PHASE4":4065,"NA":4067},{"trials":4058,"activeCount":8},[],{"trials":4060,"activeCount":8},[],{"trials":4062,"activeCount":8},[],{"trials":4064,"activeCount":8},[],{"trials":4066,"activeCount":8},[],{"trials":4068,"activeCount":8},[4069],{"nctId":4070,"briefTitle":4071,"status":63,"phases":4072,"primaryCompletion":944,"completion":4073,"start":120,"enrollment":4074,"conditions":4075,"interventions":4079},"NCT01375660","D Vitamin Intervention in VA",[44],"2014-11",205,[4076,4077,4078],"Impaired Fasting Glucose","Impaired Glucose Tolerance","Vitamin D Insufficiency",[4055],{"intervention":2962,"totalTrials":211,"cells":4081},{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4088,"PHASE4":4090,"NA":4092},{"trials":4083,"activeCount":8},[],{"trials":4085,"activeCount":8},[],{"trials":4087,"activeCount":8},[],{"trials":4089,"activeCount":8},[],{"trials":4091,"activeCount":8},[],{"trials":4093,"activeCount":8},[4094],{"nctId":2956,"briefTitle":2957,"status":63,"phases":4095,"completion":1672,"start":2959,"conditions":4096,"interventions":4097},[44],[23],[2962,2963,2964],{"intervention":4099,"totalTrials":211,"cells":4100},"Venalafaxine hydrochloride",{"EARLY_PHASE1":4101,"PHASE1":4103,"PHASE2":4105,"PHASE3":4107,"PHASE4":4109,"NA":4111},{"trials":4102,"activeCount":8},[],{"trials":4104,"activeCount":8},[],{"trials":4106,"activeCount":8},[],{"trials":4108,"activeCount":8},[],{"trials":4110,"activeCount":8},[],{"trials":4112,"activeCount":8},[4113],{"nctId":4114,"briefTitle":4115,"status":63,"phases":4116,"primaryCompletion":1602,"completion":3565,"start":4117,"enrollment":1673,"conditions":4118,"interventions":4121},"NCT00167856","Effects of Venlafaxine on Chronic Neuropathic Pain Following Spinal Cord Injury",[44],"2005-06",[4119,993,4120],"Neuropathic Pain","Spinal Cord Injuries",[4099],{"intervention":2914,"totalTrials":211,"cells":4123},{"EARLY_PHASE1":4124,"PHASE1":4126,"PHASE2":4128,"PHASE3":4130,"PHASE4":4132,"NA":4134},{"trials":4125,"activeCount":8},[],{"trials":4127,"activeCount":8},[],{"trials":4129,"activeCount":8},[],{"trials":4131,"activeCount":8},[],{"trials":4133,"activeCount":8},[],{"trials":4135,"activeCount":8},[4136],{"nctId":2904,"briefTitle":2905,"status":63,"phases":4137,"primaryCompletion":1490,"completion":656,"start":255,"enrollment":2907,"conditions":4138,"interventions":4139},[44],[17,2909,2910,2911],[2913,2914],{"intervention":4141,"totalTrials":211,"cells":4142},"insulin glargine",{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4147,"PHASE3":4149,"PHASE4":4151,"NA":4153},{"trials":4144,"activeCount":8},[],{"trials":4146,"activeCount":8},[],{"trials":4148,"activeCount":8},[],{"trials":4150,"activeCount":8},[],{"trials":4152,"activeCount":8},[],{"trials":4154,"activeCount":8},[4155],{"nctId":4156,"briefTitle":4157,"status":63,"phases":4158,"primaryCompletion":1966,"completion":1600,"start":2501,"enrollment":4159,"conditions":4160,"interventions":4161},"NCT00469833","Insulin Secretion in Diabetes Before and After Glycemic Control",[44],17,[26,3666],[4141]]